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SUMMARY 
Traditionally, ischemic stroke has been regarded as the mere consequence of 
cessation of cerebral blood flow, e.g. due to the thromboembolic occlusion of a major 
brain supplying vessel. However, the simple restoration of blood flow via 
thrombolysis and/or mechanical recanalization alone often does not guarantee a 
good functional outcome. It appears that secondary detrimental processes are 
triggered by hypoxia and reoxygenation, which are referred to as 
ischemia/reperfusion (I/R) injury. During recent years it became evident that, beside 
thrombosis inflammation and edema formation are key players in the 
pathophysiology of cerebral ischemia. The contact-kinin system represents an 
interface between thrombotic, inflammatory and edematous circuits. It connects the 
intrinsic coagulation pathway with the plasma kallikrein-kinin system (KKS) via 
coagulation factor FXII.  
The serine protease inhibitor C1-inhibitor (C1-INH) has a wide spectrum of inhibitory 
activities and counteracts activation of the contact-kinin system at multiple levels. 
The first part of the thesis aimed to multimodally interfere with infarct development by 
C1-INH and to analyze modes of actions of human plasma derived C1-INH Berinert® 
P in a murine model of focal cerebral ischemia. It was shown that C57BL/6 mice 
following early application of 15.0 units (U) C1-INH, but not 7.5 U developed reduced 
brain infarctions by ~60% and less neurological deficits in the model of transient 
occlusion of the middle cerebral artery (tMCAO). This protective effect was preserved 
at more advanced stages of infarction (day 7), without increasing the risk of 
intracerebral bleeding or affecting normal hemostasis. Less neurological deficits 
could also be observed with delayed C1-INH treatment, whereas no improvement 
was achieved in the model of permanent MCAO (pMCAO). Blood-brain-barrier (BBB) 
damage, inflammation and thrombosis were significantly improved following 15.0 U 
C1-INH application early after onset of ischemia. Based on its strong antiedematous, 
antiinflammatory and antithrombotic properties C1-INH constitutes a multifaceted 
therapeutic compound that protects from ischemic neurodegeneration in ‘clinically 
meaningful’ settings. 
The second part of the thesis addresses the still elusive functional role of 
macrophages in the early phase of stroke, especially the role of the macrophage-
specific adhesion molecule sialoadhesin (Sn). For the first time, sialoadhesin null  
(Sn-/-) mice, homozygous deficient for Sn on macrophages were subjected to tMCAO 
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to assess the clinical outcome. Neurological and motor function was significantly 
improved in Sn-/- mice on day 1 after ischemic stroke compared with wildtype (Sn+/+) 
animals. These clinical improvements were clearly detectable even on day 3 
following tMCAO. Infarctions on day 1 were roughly the same size as in Sn+/+ mice 
and did not grow until day 3. No intracerebral bleeding could be detected at any time 
point of data acquisition. Twenty four hours after ischemia a strong induction of Sn 
was detectable in Sn+/+ mice, which was previously observed only on perivascular 
macrophages in the normal brain. Deletion of Sn on macrophages resulted in less 
disturbance of the BBB and a reduced number of CD11b+ (specific marker for 
macrophages/microglia) cells, which, however, was not associated with altered 
expression levels of inflammatory cytokines. To further analyze the function of 
macrophages following stroke this thesis took advantage of LysM-Cre+/-/IKK2-/- mice 
bearing a nuclear factor (NF)-ϰB activation defect in the myeloid lineage, including 
macrophages. Consequently, macrophages were not able to synthesize inflammatory 
cytokines under the control of NF-ϰB. Surprisingly, infarct sizes and neurological 
deficits upon tMCAO were roughly the same in conditional knockout mice and 
respective wildtype littermates. These findings provide evidence that macrophages 
do not contribute to tissue damage and neurological deficits, at least, not by release 
of inflammatory cytokines in the early phase of cerebral ischemia. In contrast, Sn 
which is initially expressed on perivascular macrophages and upregulated on 
macrophages/microglia within the parenchyma following stroke, influenced functional 
outcome. 
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ZUSAMMENFASSUNG 
Der ischämische Schlaganfall wird traditionell als unmittelbare und „einfache“ Folge 
der Unterbrechung des Blutflusses zum Gehirn z.B. durch thromboembolische 
Gefäßverschlüsse gesehen. Häufig führt die alleinige Wiederherstellung des 
Blutflusses durch Lysetherapie bzw. mechanische Rekanalisation jedoch nicht zu 
einer Funktionserholung. Dies rückt sekundäre pathophysiologische Prozesse in den 
Fokus, die durch die Hypoxie und anschließende Wiederversorgung mit Sauerstoff 
angestoßen werden und zu einem sogenannten Reperfusionsschaden führen. In den 
letzten Jahren wurde klar, dass neben der Thrombenbildung Entzündungsprozesse 
und Hirnschwellung zentrale Bestandteile der Pathophysiologie von ischämischen 
Schlaganfällen sind, die über ein komplexes Netzwerk von Signalwegen eng 
miteinander verknüpft sind. An dieser Schnittstelle setzt die vorliegende Dissertation 
an. Das Kontakt-Kinin-System verbindet das plasmatische Kallikrein-Kinin-System 
(KKS), welches entzündliche und ödematöse Prozesse anstößt, über den 
Blutgerinnungsfaktor FXII mit dem intrinsischen Blutgerinnungsweg, der letztlich für 
die Thrombenbildung verantwortlich ist.  
Der endogene Serinprotease-Inhibitor C1-Inhibitor (C1-INH) besitzt ein breites 
Wirkungsspektrum und wirkt der Aktivierung des Kontakt-Kinin-Systems auf 
verschiedenen Ebenen entgegen. Ziel des ersten Teils der vorliegenden Dissertation 
war es, mittels C1-INH auf multimodale Weise ins Infarktgeschehen einzugreifen und 
die Wirkmechanismen des humanen C1-INH Berinert® P im Mausmodell nach fokaler 
zerebraler Ischämie zu untersuchen. Es konnte gezeigt werden, dass die frühe 
Behandlung von C57BL/6 Mäusen mit 15.0 Units (U) C1-INH im Modell der 
transienten Okklusion der Arteria cerebri media (tMCAO) eine drastische 
Reduzierung der Infarktvolumina um annähernd 60%, sowie deutlich weniger 
neurologische und funktionelle Defizite zur Folge hatte. Diese Schutzwirkung war 
auch im fortgeschrittenen Stadium (Tag 7) der Schlaganfallentwicklung zu 
beobachten, ohne das Risiko einer intrazerebralen Blutung zu erhöhen oder die 
normale Hämostase zu beeinflussen. Die Applikation von 7.5 U C1-INH hatte 
dagegen keinen Effekt. Ein wesentlich verbessertes neurologisches Verhalten konnte 
auch nach verzögerter Injektion von 15.0 U C1-INH erzielt werden. Im Gegensatz 
dazu bewirkte die Behandlung im Modell der permanenten MCAO (pMCAO) keine 
Verbesserung. Mechanistisch führte die Gabe von 15.0 U C1-INH zu einer deutlichen 
Stabilisierung der Bluthirnschranke und weniger Ödembildung. Darüber hinaus war 
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die lokale Entzündungsreaktion nach C1-INH-Applikation abgeschwächt und es 
bildeten sich weniger Thromben in der zerebralen Mikrozirkulation. Basierend auf 
seiner vielfältigen antithrombotischen, antientzündlichen und antiödematösen Potenz 
stellt C1-INH einen vielversprechenden Ansatz zum Schutz vor ischämischer Neuro-
degeneration nach Schlaganfall unter ‚klinisch relevanten‘ Bedingungen dar.  
Der zweite Teil der Dissertation beschäftigt sich mit der bislang ungeklärten 
funktionellen Rolle von Makrophagen in der Frühphase nach Schlaganfall, speziell 
der Rolle des Makrophagen-spezifischen Signalmoleküls Sialoadhesin (Sn). Hierzu 
wurden erstmals Sialoadhesin-defiziente (Sn-/-) Mäuse, deren Makrophagen kein Sn 
exprimieren, der tMCAO unterzogen und die klinischen Folgen bewertet. Sn-/- Tiere 
zeigten verglichen mit Wildtypen (Sn+/+) verbesserte neurologische und motorische 
Funktionen an Tag 1 nach Schlaganfall. Diese Verbesserung war auch an Tag 3 
nach Schlaganfall eindeutig nachweisbar. Die Infarkte an Tag 1 waren größenmäßig 
vergleichbar mit Sn+/+ Mäusen und nahmen bis Tag 3 nicht an Größe zu. Zu keinem 
Zeitpunkt wurde eine intrazerebrale Blutung beobachtet. 24 Stunden nach 
Schlaganfall kam es bei Sn+/+ Mäusen zu einer starken Induktion von Sn, welches im 
normalen Gehirn nur auf perivaskulären Makrophagen exprimiert wurde. Die Deletion 
von Sn auf Makrophagen wirkte einer Bluthirnschrankenstörung entgegen und hatte 
eine deutlich geringere Infiltration von CD11b+ (spezifischer Marker für 
Makrophagen/Mikroglia) Zellen ins ischämische Gewebe zur Folge. Dies war 
interessanterweise nicht mit einer Veränderung der Zytokinexpression verknüpft. Zur 
weiteren Untersuchung der Makrophagenrolle nach Schlaganfall wurde die 
Dissertation auf LysM-Cre+/-/IKK2-/- Mäuse ausgedehnt. Diese wiesen einen 
Makrophagen-spezifischen Defekt in der Aktivierung des Transkriptionsfaktors 
Nuklearfaktor (NF)-ϰB auf, und konnten folglich inflammatorische Zytokine unter der 
Transkriptionskontrolle von NF-ϰB nicht synthetisieren. Die Infarktgrößen und 
neurologischen Defizite der transgenen Tiere waren überraschenderweise 
vergleichbar mit wildtypischen Wurfgeschwistern. Diese Ergebnisse deuten darauf 
hin, dass Makrophagen zumindest nicht durch die Synthese von inflammatorischen 
Zytokinen zum Gewebeschaden und zu neurologischen Defiziten in der Frühphase 
nach Schlaganfall beitragen, während Sn, das initial nur auf perivaskulären 
Makrophagen exprimiert und später im ischämischen Parenchym auf 
Makrophagen/Mikroglia hochreguliert wird, Einfluss auf das funktionelle Outcome 
hatte.  
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1 INTRODUCTION 
1.1 Human stroke – causes and limited treatment options 
Stroke is the second leading cause of death and the most common cause of 
permanent disability worldwide (Murray & Lopez, 1997; WHO, 2008). The risk to 
experience a stroke is correlated with age (Roger et al., 2011), but due to increasing 
risk factors in our society young adults may also be affected. There are two different 
types of stroke, ischemic stroke resulting from the occlusion of a cerebral artery 
which accounts for approximately 87% of cases and which is the focus of this thesis, 
and intracerebral hemorrhage (Roger et al., 2011). Main sources of thrombo-
embolism in the brain are either blood emboli emerging from the heart due to atrial 
fibrillation (irregular heart beat) or platelet-rich thrombi arising at instable 
atherosclerotic plaques of the carotid or vertebral arteries (Green et al., 2003; Stoll & 
Bendszus, 2006; Pham et al., 2012). The primary goal of acute stroke treatment is to 
achieve restoration of blood flow as soon as possible by recanalization. The only 
approved treatment for acute ischemic stroke is intravenous (i.v.) thrombolysis with 
the clot solving agent recombinant tissue plasminogen activator (rt-PA) (NINDS, 
1995). Eligibility of acute stroke patients to rt-PA thrombolysis is low (< 10%) due to a 
narrow time window after onset of occlusion and many other contraindications (van 
den Berg & de Jong, 2009; Fulgham et al., 2004). The main exclusion criteria of 
patients from this therapy is their late arrival at the hospital (Tong et al., 2012), since 
the therapeutic time window for the effective and safe application of rt-PA is only 4.5 
hours (Hacke et al., 2008) after first symptom onset. However, the treatment with rt-
PA is associated with a risk of intracerebral hemorrhages which dramatically 
increases over time and beyond 4.5 hours neutralizes or exceeds the beneficial 
effect of recanalization (del Zoppo et al., 1992; Larrue et al., 1997). Given the 
situation that many patients are not amenable to this treatment and a significant 
number of patients with successful recanalization still develop significant neurological 
deficits (Chimowitz, 2013) additional therapeutic options are eagerly awaited in the 
clinic. 
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1.2 Pathomechanisms of ischemic stroke 
1.2.1 The ischemic cascade and its effects on the penumbra 
Acute cerebral ischemia as a result of cessation of cerebral blood flow (CBF) causes 
hypoxia and failure of the energy metabolism in the underlying brain parenchyma. 
Subsequently, a sequence of detrimental events referred to as ischemic cascade is 
initiated within minutes (Dirnagl et al., 1999). In brief, the ischemic cascade 
comprises the depolarization of neurons and glia cells due to energy failure and loss 
of membrane potential. The ionic gradient of Na+, Cl- and K+ is shifted secondary to 
intracellular Ca2+ overload, release of the excitotoxic amino acid glutamate and 
generation of reactive oxygen species (ROS), which results in cell swelling and 
disruption of membrane structures. The brain is most sensitive to reductions in blood 
supply and only a short period of impaired CBF results in irreversible damage of 
brain tissue within the core of infarction due to acute necrotic and subacute apoptotic 
cell death. The brain tissue surrounding the ischemic core, known as penumbra, is 
still alive and supplied by a partially preserved energy metabolism due to a residual 
perfusion level from adjacent non-ischemic brain areas (Astrup et al., 1981; Marchal 
et al., 1996; Baron, 1999). Hence, the penumbra might be salvaged if CBF and 
energy metabolism are restored as early as possible, which might result in less 
postischemic neurological and motor-functional deficits and improved recovery of 
patients. However, the event of reperfusion - though it is indispensable to salvage the 
penumbra - paradoxically carries the risk of serious complications. On the other 
hand, if CBF is not reestablished, brain tissue of the penumbra will definitely undergo 
irreversible damage and become part of the ischemic core (Ginsberg, 2003). 
 
1.2.2 Ischemia/reperfusion injury and experimental models of stroke 
Despite successful recanalization a large number of patients develop severe 
infarctions and neurological deficits (Chimowitz, 2013). This phenomenon is referred 
to as ischemia/reperfusion (I/R) injury and characterized by tissue damage due to 
interrupted oxygen supply and a subsequent damage caused by reperfusion. I/R 
injury depends on duration and severity of ischemia and intensity of reperfusion. 
Hence, restoration of CBF as early as possible (Hacke et al., 2008) is of great 
importance.  
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Despite extensive research over the last decades the complex mechanisms 
underlying I/R injury are less understood, but there is an increasing number of 
evidence that inflammation is critically involved (Stoll et al., 1998; Wang et al., 2007; 
Zuidema & Zhang, 2010). The event of reperfusion of ischemic tissue initiates a 
cascade of deleterious processes leading to exacerbation of the injury. Most of them 
are triggered by extensive generation of ROS before but mainly during the process of 
reperfusion. Moreover, cytokines, chemokines and other inflammatory stimuli (del 
Zoppo et al., 2000) are released upon ischemic stroke from activated endothelial 
cells and immune cells and a pronounced sterile inflammation is initiated, 
characterized by massive recruitment of polymorphonuclear leukocytes. Neutrophils 
are the first immune cells recruited to sites of injury and are detectable in the 
ischemic vasculature within hours after onset of the insult (Garcia et al., 1994; 
Bednar et al., 1997; del Zoppo, 1997; Stoll et al., 1998; Gelderblom et al., 2009). Due 
to their huge number, platelet-leukocyte-interactions and fibrin accumulation 
neutrophils might obstruct microvasculature leading to a phenomenon referred to as 
no-reflow phenomenon (del Zoppo et al., 1991). Recruited immune cells cross the 
blood-brain-barrier (BBB) and migrate into the ischemic brain tissue leading to 
extensive collateral damage and development of infarction.  
To understand the mechanisms of stroke pathophysiology several animal models of 
experimental stroke have been established. The most frequently used experimental 
model to induce focal cerebral ischemia in rodents is the occlusion of the middle 
cerebral artery (MCA) via an intraluminal thread (detailed information is provided in 
2.2.1.1) (Durukan & Tatlisumak, 2007; Carmichael, 2005). This technique, which was 
first described in 1986 in rats (Koizumi et al., 1986), and adjusted to mice (Clark et 
al., 1997), intends to imitate the human situation, since a large number of ischemic 
strokes involves the region of the MCA. The transient MCA occlusion (tMCAO), 
where the thread is withdrawn after a certain period, mimics recanalization and 
subsequent reperfusion after cessation of CBF as it is achieved in patients after 
successful thrombolysis or mechanical thrombectomy. In this model mainly the basal 
ganglia are affected, while the neocortex is involved to a variable amount depending 
on the duration of ischemia. Following removal of the thread the infarcts are 
surrounded by the penumbra, tissue that might be salvageable by reperfusion. In 
contrast, the model of permanent MCA occlusion (pMCAO), where the thread 
remains in the vessel, mimics the situation of permanent ischemia without 
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reperfusion. Here, tissue of the basal ganglia and neocortex die from ischemia, 
resulting in complete infarction of the whole MCA territory. Some experimental stroke 
studies have demonstrated that reperfusion after a certain period of brain vessel 
occlusion even resulted in larger infarctions compared with permanent ischemia 
(Aronowski et al., 1997; Yang & Betz, 1994).  
Although a single model can cover only some aspects of a heterogeneous and 
complex disease such as ischemic stroke in humans, the model of MCAO turned out 
to be useful in elucidating basic pathomechanisms involved in stroke development. 
Moreover, the model of MCAO displays several advantages: it is less invasive, since 
it does not require craniectomy (removal of a part of the skull) (Hudgins & Garcia, 
1970), the performance is simple, and it allows tissue reperfusion by withdrawing of 
the occluding filament (Braeuninger & Kleinschnitz, 2009).  
 
1.2.3 Breakdown of the blood-brain-barrier and brain swelling 
I/R injury following focal cerebral ischemia is accompanied by breakdown of the 
blood-brain-barrier (BBB) (Stoll & Jander, 1999). Products abundantly released and 
generated during the process of reperfusion degrade integral transmembrane 
proteins of the BBB, such as occludin, which is an important structural element 
between adjacent endothelial cells, the so called tight junctions. Consequently, major 
BBB properties, such as regulation of vascular barrier functions and vascular tone as 
well as control of hemostatic functions and immune cell trafficking are lost. 
Importantly, loss of the metabolic and physical barrier between circulation and brain 
tissue results in brain swelling, another pathophysiological component in stroke 
development. There are two major types of edema, (1) the intracellular cytotoxic 
edema and (2) the extracellular vasogenic edema (Ayata & Ropper, 2002). 
Formation of cytotoxic edema occurs within minutes after stroke onset in the 
ischemic core. This is primarily a consequence of water shift from the extracellular to 
the intracellular space. Since there is no change in the water content within the brain 
parenchyma, formation of cytotoxic edema does not induce brain swelling and occurs 
independently from BBB disruption. In contrast, vasogenic edema contributes 
significantly to formation of brain swelling and is caused by lost integrity of the BBB 
leading to leakage of fluids and proteins from intravascular to extravascular spaces 
(Rosenberg & Yang, 2007). Depending on the degree of water influx brain swelling 
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compresses midline structures and adjacent brain tissue (Aiyagari & Diringer, 2002) 
(Fig. 1), which results in secondary deterioration of patients. This is often the case in 
‘malignant’ cerebral infarction, which completely involves the territory of the MCA 
(~10% of stroke cases). It represents a major life-threatening event with a mortality 
rate of approximately 80% (Hacke et al., 1996; Berrouschot et al., 1998) and usually 
becomes manifest within the first 72 hours after stroke onset (Shaw et al., 1959; Ng 
& Nimmannitya, 1970; Qureshi et al., 2003). Thus, in the subacute stage of infarct 
development, brain edema formation accounts for a significant number of additional 
stroke victims. Conventional antiedematous treatments such as corticosteroids are 
not effective in this situation since the glucocorticoid receptors are degraded 
(Kleinschnitz et al., 2011). 
 
Figure 1: A) Cranial computed tomography (CT) scan of a patient 24 hours after a complete 
media infarct (red line). B) CT scan of the same patient 3 days post stroke, who underwent 
craniectomy within 48 hours to relieve the pressure of the developing infarct swelling (red line).  
C) CT scan of a patient 3 days after a complete media infarct without craniectomy due to relevant 
contraindications. The edema formation (red line) following stroke resulted in a midline shift with 
compression of the intact contralateral hemisphere. 
 
1.3 The contact-kinin system 
The contact-kinin system constitutes a framework of different plasma proteins, the 
coagulation factor FXII (Hageman factor), plasma prekallikrein (PK), coagulation 
factor FXI and high molecular weight kininogen (HMWK) (Cochrane & Griffin, 1982). 
In recent years it became evident that the contact-kinin system plays an important 
role in the pathophysiology of I/R injury after cerebral ischemia (Storini et al., 2005). 
Stroke outcome could be improved by deletion of the gene encoding bradykinin 
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receptor 1 (B1R) (Austinat et al., 2009) in transgenic mice or the serine protease 
kininogen (Langhauser et al., 2012). The protective effect was due to reduced edema 
formation and diminished inflammatory cell recruitment. Mice with a genetic 
disruption or pharmacological inhibition of FXII were similarly protected from ischemic 
stroke (Kleinschnitz et al., 2006; Hagedorn et al., 2010). FXII represents an interface 
between the plasma kallikrein-kinin system (KKS) and the intrinsic pathway of blood 
coagulation (reviewed in Schmaier, 2008) (Fig. 2).  
 
 
Figure 2: Scheme of the plasma kallikrein-kinin system (KKS) and intrinsic coagulation pathway 
initiated by FXIIa. Plasma KKS is initiated by FXIIa-mediated conversion of the inactive precursor 
plasma PK into its active form plasma kallikrein (Mandle & Kaplan, 1977; Revak et al., 1978). 
Plasma kallikrein in turn reciprocally activates additional FXII (Cochrane et al., 1973; Griffin, 
1978) and liberates BK through cleavage of the precursor kininogen HMWK (Wiggins, 1983). BK 
preferentially binds to B2R, a G-protein coupled transmembrane receptor (GPCR). By actions of 
CP BK is converted into its active metabolite des-Arg9-BK, the physiological agonist of GPCR 
B1R (Rodi et al., 2005). Binding of BK and des-Arg9-BK to B1R and B2R on the ECM mediates 
signaling of inflammatory processes and edema formation by increased vascular permeability. 
FXII triggers the sequential activation of the zymogens FXI, FIX, FX and prothrombin. Cleavage 
of fibrinogen by thrombin leads to generation of the single molecule fibrin, which then 
accumulates with other fibrin molecules to form a fibrin clot. C1-INH counteracts activation of 
FXIIa, FXIa and plasma kallikrein. FXII/FXI/FIX/FX (coagulation factors XII/XI/IX/X, a: activated 
form), PK (prekallikrein), HMWK (high molecular weight kininogen), (des-Arg9)-BK ((des-
Arginin9)-bradykinin), B1R/B2R (bradykinin receptor 1/2), CP (carboxypeptidase), C1-INH (C1-
inhibitor), endothelial cell membrane (ECM). 
Introduction 
7 
 
Following ischemic stroke, FXII is activated (FXIIa) and triggers activation of plasma 
KKS leading to release of extremely short-living peptides bradykinin (BK) and des-
Arginin9-BK (Décarie et al., 1996). Upon their binding to B2R and B1R, respectively 
on the endothelial cell membrane (ECM) several intracellular signaling pathways are 
triggered. Some stimulate cellular release of nitric oxide (NO), prostacyclin, histamine 
and superoxide (Hong, 1980; Holland et al., 1990; Sarker et al., 2000; Ignjatovic et 
al., 2004), which also affect the vascular system and lead to enhanced vascular 
permeability and plasma extravasation but also mediation of typical inflammatory 
symptoms such as pain, redness and swelling.  
Furthermore, FXIIa triggers activation of the intrinsic coagulation pathway, which 
culminates in generation of the single molecule fibrin by cleavage of fibrinogen. 
Single fibrin molecules then assemble with each other to form a fibrin clot (Furie & 
Furie, 1992) (Fig. 2). 
The involvement of BK release in brain injury had been demonstrated in models of 
global and focal cerebral ischemia (Kamiya et al., 1993; Relton et al., 1997; Xia et al., 
2004; Gröger et al., 2005) and all components of the KKS had been identified in the 
brain of laboratory animals. Moreover, KKS activation was described in human brain 
following ischemic stroke (Wagner et al., 2002). 
 
1.4 C1-inhibitor and its spectrum of activities 
C1-inhibitor (C1-INH) represents one of the main natural inhibitors of FXIIa and 
plasma kallikrein of the plasma KKS and controls activation of FXIa (Schapira et al., 
1982; Pixley et al., 1985; Wuillemin et al., 1995) (Fig. 2). Hence, C1-INH regulates 
swelling via controlled liberation of BK, and the release of inflammatory mediators in 
healthy individuals.   
C1-INH represents a single chain polypeptide of 478 amino acids and belongs to the 
superfamily of serine protease inhibitors (serpins) (Bock et al., 1986; Davis III, 1988). 
The main function of C1-INH is the regulation of serine protease activity, but it is also 
involved in several non-covalent interactions that are independent from protease 
inhibition. C1-INH consists of two distinct domains, a serpin-domain containing the 
reactive center loop responsible for its serine protease inhibitory function, and an 
amino-terminal heavily glycosylated domain.  
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Deficiency or dysfunction of C1-INH causes hereditary angioedema (HAE) type-1 or 
type-2 which is a relatively rare and partly life-threatening disease (Carugati et al., 
2001). HAE is characterized by recurrent events of acute local swelling attacks due 
to a reversible increase of vascular permeability that may affect any area of the skin, 
abdomen or respiratory tract (Bork et al., 2003). Acute attacks of HAE can be treated 
by replacement therapy with C1-INH concentrate to restore normal functional levels 
of C1-INH (Waytes et al., 1996). 
Over the past decades different C1-INH concentrates have been tested in humans 
(Cicardi et al., 2007). One of them is the pasteurized and purified preparation 
Berinert® P (CSL Behring, Marburg), which is derived from human plasma and 
approved by the Food and Drug Administration (FDA) for treatment of acute attacks 
of HAE since 2009 in Europe, Argentina, Australia and North America (Craig et al., 
2009). Based on the properties of C1-INH Berinert® P in blocking components of the 
plasma KKS, this study addresses the question whether C1-INH application could 
ameliorate the clinical outcome of mice in the tMCAO stroke model.  
 
1.5 Immune responses in cerebral ischemia 
1.5.1 Cellular infiltration upon breakdown of the blood-brain-barrier 
Breakdown of the BBB during cerebral ischemia allows access of blood components 
to the perivascular space and cellular infiltration into the brain parenchyma. The first 
hematogenous (blood-born) cells penetrating the brain in a time-coordinated fashion 
are neutrophils (Stoll et al., 1998; Bednar et al., 1997; del Zoppo, 1997; Garcia et al., 
1994; Gelderblom et al., 2009) followed by monocytes/macrophages (Garcia et al., 
1994; Schroeter et al., 1994; Jander et al., 1995; Schroeter et al., 1997; Schilling et 
al., 2003; Gelderblom et al., 2009; Gliem et al., 2012) and T lymphocytes (Schroeter 
et al. 1994; Jander et al., 1995).  
The resident macrophages of the brain are microglia, a cell type that, if seen under 
steady state conditions (non-inflamed, non-activated), differs morphologically and 
phenotypic from the hematogenous macrophages (Perry & Gordon, 1991). Upon 
activation following cerebral ischemia microglia undergo morphological changes and 
migrate to sites of injury, where they become indistinguishable from infiltrating 
phagocytosing macrophages (Perry et al., 1993; Stoll et al., 1998). Once activated 
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immune cells have the potential to secrete a set of various pro- and antiinflammatory 
mediators. 
The perivascular compartment contains a special subtype of macrophages, the 
‘perivascular’ macrophages. Their functional role is largely unknown, but evidence in 
experimental autoimmune encephalomyelitis suggests that perivascular 
macrophages may present antigens to brain-infiltrating T cells. In the normal brain, 
perivascular macrophages express a unique adhesion molecule, sialoadhesin (Sn) 
(Hartnell et al., 2001).  
 
1.5.2 The macrophage-restricted adhesion molecule sialoadhesin 
Sn is a signaling molecule that, in contrast to many others, is restricted to 
macrophage-like cells (Crocker & Gordon, 1986, 1989; Hartnell et al., 2001) and 
hence, thought to be involved in macrophage-specific functions. Sn belongs to the 
superfamily of sialic acid immunoglobulin (Ig)-like lectins (siglec) and was discovered 
by Crocker and Gordon (1985, 1986). It specifically binds to sialic acids (negatively 
charged carbohydrate residues) on the cell surface of glycoproteins 
(sialoglycoproteins) (Crocker & Gordon, 1989). Sn (other names: siglec-1 or CD169) 
has a molecular weight of 185 kDa and consists of 17 extracellular Ig-like domains, a 
transmembrane domain and a relatively short cytosolic domain (Crocker et al., 1994). 
Sn is missing any inhibitory tyrosine-based motifs, unlike most other members of the 
siglec family (Crocker et al., 2007). The extracellular region can be further 
categorized into the N-terminal single V-set domain, containing the sialic acid-binding 
site (Vinson et al., 1996) and 16 C2-set domains (Crocker et al., 1994) (Fig. 3).  
Besides its expression on specific subpopulations of macrophages at different levels 
in normal tissue (Crocker & Gordon, 1986, 1989; Hartnell et al., 2001), Sn expression 
has also been observed on inflammatory macrophages within injured tissue in 
different disorders (Pope et al., 1998; Gijbels et al., 1999; Jiang et al., 1999; Nath et 
al., 1999; Hartnell et al., 2001; Ip et al., 2007). In contrast, resident brain microglia 
cells under steady-state conditions do not express detectable Sn levels (Perry et al., 
1992). The molecular architecture of Sn and its high conservation from mouse to 
human (Hartnell et al., 2001) suggest a role in mediating cell-cell interactions 
(Crocker et al., 1990, 1995; Hartnell et al., 2001), especially during inflammation.    
Introduction 
10 
 
To assess the role of Sn in stroke development this study took advantage of mice 
deficient for Sn.  
      
 
1.6 Aim of the study 
The contact-kinin system, as recently shown, is critically involved in the 
pathophysiology of I/R injury in the brain and represents an interface via FXIIa 
between the key processes brain swelling, inflammation, and thrombosis. In this 
context, blocking of distinct members of the contact-kinin system has the potential to 
become an effective strategy to combat neurological disorders like ischemic stroke. 
Following breakdown of the BBB after focal cerebral ischemia a massive infiltration of 
macrophage-like cells and other immune cells into the brain is initiated. Until today, 
signaling molecules involved in macrophage activation and cell communication in 
brain stroke are elusive. 
Therefore, this thesis addresses two key questions: (1) Is it possible to influence the 
outcome of cerebral ischemia by a multifaceted C1-inhibitor (C1-INH), already 
clinically approved for human use in a different indication (hereditary angioedema)? 
For this purpose, human plasma derived C1-INH Berinert® P was used at two doses 
of 7.5 U and 15.0 U, respectively. The efficacy of C1-INH was analyzed in a model of 
tMCAO in C57BL/6 mice with application of the inhibitor 1 hour and 6 hours, 
respectively after onset of ischemia as well as in a model of pMCAO with C1-INH 
application 1 hour post stroke. The neurological outcome of mice upon cerebral 
ischemia was evaluated by means of functional scoring and survival rate, 
Figure 3: Structural features 
of sialoadhesin (Sn). The N-
terminal single V-set Ig 
domain contains the sialic 
acid-binding site and is 
followed by 16 C2-set Ig 
domains, the transmembrane 
domain and a relatively short 
cytosolic domain. 
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measurement of infarct volume and brain swelling, and analysis of BBB disruption, 
microvascular thrombosis and postischemic inflammation.  
(2) What is the functional contribution of macrophage-restricted sialoadhesin (Sn) to 
ischemic brain injury in mice? To address the role of Sn in breakdown of the BBB 
and stroke development following tMCAO the study took advantage of Sn deficient 
mice. For further advancement of the analysis of macrophage-specific contribution to 
stroke development, conditional knock-out mice with a non-functional transcription 
factor nuclear factor (NF)-ϰB within the myeloid cell lineage were included in the 
tMCAO study. The neurological outcome of transgenic mice upon cerebral ischemia 
was evaluated by means of functional scoring, determination of infarct size and 
analysis of BBB disruption and postischemic inflammation. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Biological reagents 
C1-INH (Berinert® P) (CSL Behring GmbH, Marburg) 
Goat serum (DakoCytomation) 
POD biotinylated peroxidase (Vector Laboratories) 
Proteinase inhibitor (Roche) 
 
2.1.2 Buffers 
All buffers were prepared and diluted in double distilled water (ddH2O). 
 
 General buffers 
4% PFA (pH 7.4) 
1.33 M PFA  
1 drop NaOH 
 
2% TTC 
60 mM TTC 
 
PBS (pH 7.4) (10x stock) 
1.37 M NaCl 
26.8 mM KCl 
100 mM Na2HPO4 
115 mM NaH2PO4 x H2O 
 
PBST (pH 7.4) (10x stock) 
PBS (10x stock) 
0.05% Tween® 20 
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 Buffers for electrophoresis 
2x sample loading buffer (pH 6.8) 
120 mM TRIS 
10% SDS  
20% Glycerine 
20% β-Mercaptoethanol  
Tip of a spatula of bromophenol blue 
 
Running buffer (10x stock) 
35 mM SDS 
250 mM TRIS 
1.92 M Glycine 
 
TAE buffer (50x stock)                
2 M TRIS 
0.05 M EDTA 
0.05% acetic acid 
 
 Buffers for protein isolation 
RIPA buffer (pH 7.4)                
25 mM TRIS 
150 mM NaCl 
1% NP-40  
0.1% SDS 
 
 Buffers for semi dry blotting and development of immunoblots 
Blocking buffer (10x stock) 
PBST (10x stock) 
5% milk powder 
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Blotting buffer (10x stock) 
1.92 M Glycine 
250 mM Tris 
ad 1 l ddH2O 
16.66% MeOH 
 
Stripping buffer 
15% H2O2 in 1x PBST 
 
Washing buffer (10x stock)  
see PBST (10x stock) 
 
2.1.3 Chemicals 
Acetone (Sigma-Aldrich) 
Acidic acid (Sigma-Aldrich) 
Agarose (Sigma) 
APS (Merck) 
Aqua ad injectabilia (Braun)  
Aquatex (Merck) 
BCA (Sigma) 
BSA (Sigma) 
Bromophenol blue (Sigma) 
Chloroform (Sigma-Aldrich)  
Copper(II)sulfate solution (Sigma) 
Tissue Tec® (Sakura Finetek) 
DEPC-water (RNase-free) (Ambion) 
DAB (Kem-En-Tec Diagnostics) 
ECLplus (GE Healthcare) 
EDTA (Sigma) 
Eosin G. (Millipore) 
EtOH (Sigma-Aldrich) 
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Ethidium bromide (Sigma-Aldrich) 
Evans blue dye (Sigma-Aldrich) 
Glycerine (Merck) 
Glycine (Sigma)  
Hematoxylin solution (Millipore) 
Hydrogen peroxide 30% (Merck) 
Isoflurane  (Abbott or CP Pharma, respectively) 
Isopropyl alcohol (Sigma-Aldrich) 
KCl (Merck) 
Ketamin 10% (Sigma-Aldrich) 
β-Mercaptoethanol (Merck) 
Methanol (Sigma-Aldrich) 
Milk powder (Roth) 
Mowiol 4-88 Reagent (Calbiochem) 
NaCl (Sigma-Aldrich) 
NaCl 0.9% in aqua ad injectabilia, isotonic (Diaco) 
Na2HPO4 (Merck) 
NaH2PO4 x H2O (Merck) 
NaOH (Merck) 
NonidetTMP40 (NP-40) Substitute (for RIPA buffer) (Sigma) 
PFA (Sigma) 
Rotiphorese®Gel 30 (Roth) 
Rompun 2% (Bayer Health Care) 
SDS (Merck) 
Sucrose (Merck) 
TEMED (Sigma) 
TRIS (Merck) 
Triton-X-100 (Sigma-Aldrich) 
TRIzol® Reagent (Invitrogen)  
TTC (Sigma-Aldrich) 
Tween®20 (Roth) 
Vitro Clud® (R. Langenbrinck Labor- und Medizintechnik) 
Xylene (Sigma-Aldrich) 
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2.1.4 Kits 
 DNA amplification 
PCR Mastermix (2x) MaximaTM Hot Start Green (Fermentas)  
The following compounds were already mixed in a ready to use - solution:             
dATP, dGTP, dCTP, dTTP, MgCl2, and Taq DNA-Polymerase 
 
 DNA purification 
DNeasy Blood & Tissue Kit 250 (Qiagen; 69506) 
Contains ATL-buffer, Proteinase K, AL buffer, AW1 buffer, AW2 buffer, AE buffer and 
collection tubes  
 
 Immunoblot development 
ECLplus (GE Healthcare, RPN2132) 
 
 Immunoperoxidase staining 
Avidin/Biotin blocking solution (Avidin/Biotin Blocking Kit, Sp-2001, Vector 
Laboratories) 
 
 Reverse transcription (cDNA synthesis) 
TaqMan® Reverse Transcription Reagents (Applied Biosystems; N808-0234): 
MuLV Reverse Transkriptase; N808-0018; 50 U/µl 
RNAse Inhibitor; N808-0119; 20 U/µl 
Random Hexamer; N808-0127; 50 µm 
GeneAMP dNTP Blend 10 mM; N808-0260 
GeneAMP 10x PCR buffer II (500 mM KCl, 100mM Tris/HCl pH 8.3) + MgCl2 (25 
mM); N808-0130 
 
 Semiquantitative RT-PCR 
TaqMan® 2x PCR Master Mix; Applied Biosystems; 4304437 (5 ml) 
TaqMan® Predeveloped Assay Reagents (primer) for gene expression; Applied 
Biosystems 
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Table 1: Mouse primer used for semiquantitative RT-PCR 
Primer Part Number Reporter Quencer 
GAPDH  4352339E VIC MGB 
Edn-1 Mm00438656_m1 FAM MGB 
IL-1β Mm00434228_m1 FAM MGB 
IL-10 Mm00439616_m1 FAM MGB 
TGFβ-1 Mm00441724_m1 FAM MGB 
TNF-α Mm00443258_m1 FAM MGB 
 
2.1.5 Markers 
Precision Plus ProteinTM Dual Color Standards (Biorad) 
DNA ladder 1 kb (peqlab) 
 
2.1.6 Animals 
Mice were housed in plastic cages with access to food and water ad libitum and kept 
under specific pathogen-free conditions at the Department of Neurology, University 
Clinic, Würzburg. All animal procedures were approved by the responsible animal 
care committee of the University of Würzburg and the appropriate authorities of the 
State of Bavaria (Regierung von Unterfranken). 
 
C57BL/6 mice 
C57BL/6 is the most widely used inbred strain and the first to have its genome 
sequenced (Mouse Genome Sequencing Consortium, 2002). C57BL/6 mice are 
commonly used in the production of transgenic (TG) mice. Overall, C57BL/6 mice 
breed well, are long-lived, and have a low susceptibility to tumors. Adult male 
C57BL/6N mice were purchased from Charles River (Sulzfeld, Germany). 
 
Genetically modified mice 
As TG mice only mice, which are homozygous deficient for the target gene were 
used in this study. All TG strains have been backcrossed onto a C57BL/6 
background (C57BL/6N or C57BL/6J, respectively) for at least 8 generations. 
Wildtype (WT) littermates served as controls. 
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Sialoadhesin deficient (Sn-/-) mice 
Sn-/- mice possess a deletion in both alleles of the adhesion molecule sialoadhesin 
(Sn), which is restricted to macrophage-like cells.  
Sn-/- mice, backcrossed onto a C57BL/6N background for at least eight generations, 
were obtained from Paul Crocker and generated as previously described (Oetke et 
al., 2006) by conventional gene-targeting in embryonic stem cells using homologous 
recombination. In brief, the Sn gene was disrupted via insertion of a neomycin 
resistance gene expression cassette. Sn-/- mice were genotyped for insertion of the 
neomycin cassette by conventional PCR, which resulted in a 1729 base pairs (bp) 
product for the mutated allele (Fig. 4) in Sn-/- mice. The WT allele (size 468 bp) was 
absent, indicating that Sn-/- mice used in this study were homozygous deficient for 
Sn. 
 
  
 
Sn-/- have been first described in 2006 as a viable strain, exhibiting only a mild 
phenotype. Sn-/- mice displayed relatively increased numbers of CD8+ T cells, 
accompanied by little decreased numbers of B220+ B cells in spleen and lymph 
nodes. Levels of IgM were found to be reduced by about 50% compared with WT 
(Sn+/+) mice (Oetke et al., 2006). 
 
Nuclear factor-kappa B (NF-ϰB) defective (LysM-Cre+/-/IKK2fl/fl) mice 
LysM-Cre+/-/IKK2fl/fl mice bear a myeloid cell type-specific deletion of the inhibitor of 
NF-ϰB (IϰB) kinase 2 (IKK2), the activator of NF-ϰB resulting in an activation defect 
of NF-ϰB in mature macrophages, microglia and granulocytes. LysM-Cre+/-/IKK2fl/fl 
mice onto a C57BL/6J background were generated as previously described (Kanters 
et al., 2003) using the bacteriophage P1-derived Cre/lox P recombination system.  
Figure 4: Representative agarose gel-
electrophoresis of DNA from Sn-/- mice 
with insertion of the neomycin resistance 
gene expression cassette into the Sn 
gene. The mutated allele has a size of 
1729 bp (TG-bond). The wildtype bond at 
468 bp was absent. 
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In brief, mice carrying two floxed (fl) IKK2 alleles (flanked by loxP sites; IKK2fl/fl) 
(Pasparakis et al., 2002) have been crossed with LysM-Cre+/- knock-in mice (Clausen 
et al., 1999), expressing Cre-recombinase under the control of an endogenous 
lysozyme M promotor in the myeloid cell lineage.  
LysM-Cre+/-/IKK2fl/fl mice, homozygous for the IKK2 deletion in cells of the myeloid 
lineage, are viable, fertile, standard in size and do not display any immoderate 
physical or behavioral abnormalities. As WT littermates served LysM-Cre-/-/IKK2fl/fl 
mice. LysM-Cre+/-/IKK2fl/fl mice and coeval WT littermates (LysM-Cre-/-/IKK2fl/fl) were 
obtained from Prof Dr Stefan Frantz, University Clinic, Würzburg and had been 
successfully tested for deletion of the IKK2 gene in his laboratory.  
 
2.1.7 Anesthesia  
Inhalation 
2.5% isoflurane in a 70% N2O/30% O2 mixture 
 
Intraperitoneal (i.p.) injection 
10% Ketamine   500 µl (0.8%) 
  2% Rompun   250 µl (0.08%) 
        NaCl (0.9%) 5500 µl (0.8%) 
 
2.1.8 Gels 
Table 2: Composition of polyacrylamide gels 
 Separating gel (12%) Stacking gel (5%) 
ddH2O  1.65 ml 1.35 ml 
Rotiphorese®Gel 30 2 ml 0.335 ml 
1.5 M TRIS pH 8.8 1.25 ml - 
1 M TRIS pH 6.8 - 0.25 ml 
10% SDS 0.05 ml 0.02 ml 
10% APS 0.05 ml 0.02 ml 
TEMED 0.004 ml 0.004 ml 
 
 
 
Inject 10 µl/g of mouse body weight  
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Table 3: Composition of agarose gel (2%) 
 medium (200 ml) large (300 ml) 
Agarose 4 g 6 g 
1x TAE 200 ml 300 ml 
EtBr 20 µl 30 µl 
 
2.1.9 Antibodies and dyes 
Table 4: Primary antibodies 
 Antibody Company Part number Labeling 
Anti-Fibrinogen pAb rabbit anti-
mouse 
Acris Antibodies AP00766PU-N - 
Anti-Occludin pAb rabbit anti-
mouse 
Abcam ab31721 - 
Anti-β-Actin mAb mouse 
anti-mouse 
Sigma-Aldrich A5441 - 
Anti-CD11b mAb rat anti-
mouse 
AbD Serotec MCA711 - 
Anti-Ly-6B.2 
alloantigen 
mAb rat anti-
mouse 
AbD Serotec MCA771GA - 
Anti-CD169 mAb rat anti-
mouse 
Serotec MCA884 - 
Anti-CD11b mAb rat anti-
mouse 
Serotec MCA74B Biotin 
 
Table 5: Secondary antibodies 
 Antibody Company Part number Labeling 
Anti-IgG pAb rabbit anti-
mouse 
Vector 
Laboratories 
BA-4001 Biotin 
Anti-IgG pAb goat anti-
rabbit 
Dianova/Jackson 111-165-144 Cy3 
Anti-IgG pAb goat anti-
rabbit 
Abcam ab96883 DyLight® 488 
Anti-IgG pAb donkey 
anti-rabbit 
Dianova/Jackson 711-035-152 HRP  
Anti-IgG pAb donkey 
anti-mouse 
Dianova/Jackson 715-035-150  HRP 
Anti-IgG pAb goat anti-
rat 
Abcam Ab98386 DyLight® 488 
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Fluorescent dyes 
Cy3-labeled streptavidin (Biozol, CLCSA1010) 
Hoechst dye (Sigma-Aldrich, 33342) 
 
2.2 Methods 
2.2.1 In vivo experiments 
2.2.1.1 Induction of focal cerebral ischemia in mice 
All experiments were conducted according to the recommendations for research in 
mechanism-driven basic stroke studies (Dirnagl, 2006). 
Male C57BL/6N mice (6-8 weeks), Sn-/- mice (8-12 weeks) or LysM-Cre+/-/IKK2fl/fl 
mice (8-12 weeks), respectively and coeval WT littermates underwent transient 
middle cerebral artery occlusion (tMCAO) to induce focal cerebral ischemia (Clark et 
al., 1997; Kleinschnitz et al., 2010a). Additionally, C57BL/6N mice were subjected to 
permanent middle cerebral artery occlusion (pMCAO) (Pham et al., 2010). 
For performance of MCAO mice were anesthetized through a silicon tube with an 
isoflurane/oxygen mixture (Anesthesia Unit, Abbott, Vapor 19.1) and placed under 
the operating microscope (OPMI 6-CFC; Carl Zeiss AG) in supine position on a 
feedback controlled heating device (TSE Systems TempControl II) to maintain the 
animals’ body temperature at 37 °C throughout surgery. After a midline skin incision 
in the neck and stepwise shifting of adjacent connective tissue, the right common 
carotid artery (CCA) was exposed. The proximal external (ECA) and internal carotid 
arteries (ICA) were dissected from surrounding tissue (Fig. 5A). Then, the proximal 
CCA and the ECA were ligated and a non-permanent ligature was loosely tied 
around the distal CCA (Fig. 5B) using appropriate sterile silk suture material (3-0,    
4-0, and 7-0). Finally a vessel clip (Fine Science Tools Inc., Foster City, CA, USA) 
was applied to the proximal ICA (Fig. 5B) to isolate a stretch of the artery from blood 
circulation between the proximal CCA ligature and the vessel clip. Following incision 
in this part of the blood vessel, a standardized silicon rubber-coated 6.0 nylon 
monofilament (6021; Doccol Corporation, Redlands, USA) was inserted (Fig. 5C). 
Upon removal of the vessel clip, the monofilament was advanced via the right ICA to 
occlude the origin of the middle cerebral artery (MCA) and thereby interrupting 
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cerebral blood flow to the territory of the MCA. Immediately after positioning of the 
monofilament mice in the tMCAO model were allowed to wake up in an isolated cage 
under heating control (heating device, Nagel GmbH). After 60 min the animals were 
reanaesthetized and the occluding monofilament was withdrawn to allow reperfusion. 
Finally, wounds were properly sutured using appropriate silk suture material (4-0) 
(Braeuninger et al., 2012).  
For pMCAO, the occluding monofilament was left in situ and wounds were properly 
sutured. The monofilament was removed immediately before sacrificing the animals, 
i.e. 24 hours after onset of MCAO. The average operation time for MCAO per animal 
was 8 min and never exceeded 13 min.  
Animals whose proximal CCA and ECA were ligated without occlusion of the MCA 
served as sham-operated mice.  
 
Figure 5: Representative images of the MCAO operating procedure. A) Exposed right common 
carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) next to the 
trachea. Image modified from Braeuninger et al., 2012. B) Permanent ligature and non-
permanent ligature applied to the ECA or CCA, respectively plus vessel clip applied to the ICA.  
C) Insertion of a silicon-coated monofilament in the CCA. Images (B, C) are kindly provided by Dr 
Friederike Langhauser. 
 
2.2.1.2 Assessment of functional outcome in mice 
Global neurological status of mice was determined according to Bederson et al. 
(1986a) (Tab. 6). Motor function and coordination of mice were graded using the grip 
test score (Moran et al., 1995) (Tab. 6). Therefore, mice were placed midway on a 
string of 50 cm length that stuck between two vertical supports, elevated 40 cm from 
the flat surface, and rated by a blinded investigator. 
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Table 6: Score system of the Bederson score and grip test score to evaluate neurological or 
motor function and coordination, respectively in mice. 
Test Score Description 
Bederson score 0 no deficit 
1 forelimb flexion 
2 forelimb flexion plus decreased resistance to lateral push 
3 unidirectional circling 
4 longitudinal spinning 
5 no movement 
 
Grip test score 0 falls off the string 
1 hangs onto string by one or both fore paws 
2 
hangs onto string by one or both fore paws and attempts to climb 
onto string 
3 
hangs onto string by one or both fore paws plus one or both hind 
paws  
4 
hangs onto string by fore and hind paws plus tail wrapped around 
string 
5 escape (to the supports) 
 
2.2.1.3 Application of human plasma derived C1-inhibitor Berinert® P 
One hour after induction of tMCAO or pMCAO or 6 hours after induction of tMCAO, 
C57BL/6N mice received a single intravenous (i.v.) injection of human plasma 
derived C1-inhibitor (C1-INH) Berinert® P at a dose of 7.5 units (U) or 15.0 U, 
respectively, diluted in 150 µl aqua ad injectabilia (carrier solution). The respective 
doses were chosen based on previously published work in rodent models of cerebral 
ischemia and 15.0 U corresponds to the amount of C1-INH required to obtain 90% to 
95% inhibition of complement hemolytic activity in mice (De Simoni et al., 2003; 
Storini et al., 2005; Longhi et al., 2009). 
 
2.2.1.4 Stroke assessment by magnetic resonance imaging 
Serial magnetic resonance imaging (MRI) is a non-invasive method to determine 
infarct volumes and the dynamics of infarct development in living animals. Using a 
protocol for detection of bleeding, which included blood-sensitive T2*weighted (T2*w) 
gradient-echo images presenting ischemic lesions as hyperintense (bright) areas 
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(Kleinschnitz et al., 2006), secondary hemorrhagic transformation in living animals 
can be assessed. 
MRI in mice was performed repeatedly after tMCAO on a 1.5-Tesla MR unit (Vision, 
Siemens). For this purpose anesthetized (isoflurane) mice were placed in supine 
position on a heating device (TSE Systems TempControl II) (Kleinschnitz et al., 2006, 
2007). A custom-made dual channel surface coil (A063HACG, Rapid Biomedical, 
Würzburg) was placed on their head for further examination, while inhalation 
anesthesia was maintained throughout imaging. The image protocol included a 
coronal T2*w sequence (slice thickness 2 mm) and a blood-sensitive coronal 3D 
T2*w gradient-echo constructed interference in steady state (CISS; slice thickness 1 
mm) sequence. MR images were transferred to an external workstation (Leonardo; 
Siemens) for data processing, and were assessed blinded to group assignment with 
respect to infarct morphology and the occurrence of intracerebral bleeding. Infarct 
volumes were calculated by planimetry of the hyperintense (bright) area on high-
resolution CISS images. MRI was carried out in cooperation with Dr Csanad Varallay 
and Virgil Michels.  
 
2.2.1.5 Tail bleeding assay 
Anesthetized (ketamine/rompun) C57BL/6N mice were injected with 15.0 U C1-INH 
or vehicle, respectively. After 15 min, a distal 2 mm segment of the tail tip was 
amputated with a scalpel. Bleeding was recorded by gently absorbing blood drops 
every 20 sec with filter paper (WhatmanTM, GE Health Care), without touching the 
wound surface. Bleeding time was stopped immediately after cessation of bleeding 
(Renné et al., 2005). 
 
2.2.2 Physiological parameters 
C57BL/6N mice were controlled for several physiological parameters as blood 
pressure, heart rate, and arterial blood gases, which can critically affect stroke 
outcome. 
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2.2.2.1 Invasive hemodynamics 
For assessment of blood pressure and heart rate, C1-INH (7.5 U or 15.0 U, 
respectively)-treated mice and vehicle-treated Ctrl mice were placed on a heating 
device (TSE Systems TempControl II) to maintain normothermia (37 °C) and 
anaesthetized by i.p. injection of ketamine/rompun. A high-fidelity 1.4 microtip 
catheter (Millar Instruments) was inserted into the right carotid artery and advanced 
into the left cardiac ventricle. Correct positioning of the catheter was assessed by 
continuous monitoring of the pressure waveform. Hemodynamic data were digitized 
at 4000 Hertz via a MacLab system (AD Instruments) connected to an Apple G4 
PowerPC computer and analyzed (Engelhardt et al., 1999; Brede et al., 2011). This 
experiment was performed in cooperation with Dr Mark Brede. 
 
2.2.2.2 Blood gas analysis 
An arterial blood sample of 150 µl was drawn from the left cardiac ventricle of C1-INH 
(7.5 U or 15.0 U, respectively)-treated mice and vehicle-treated Ctrl mice following 
i.p. anesthesia with ketamine/rompun via a heparinized syringe. Arterial pH, PaCO2 
(mm Hg), and PaO2 (mm Hg) were measured using an ABL 77 automated blood gas 
analyzer (Radiometer Medical) (Kleinschnitz et al., 2007). This experiment was 
performed in cooperation with Dr Mark Brede. 
 
2.2.3 Transcardially perfusion of mice 
To remove blood from vessels in order to avoid interference with histological 
stainings TG mice (Sn-/-, LysM-Cre+/-/IKK2fl/fl) and WT littermates (Sn+/+, LysM-Cre-/-
/IKK2fl/fl) were deeply anesthetized with i.p. injection of ketamine/rompun and 
transcardially perfused immediately after animals had been tested negatively for 
reflexes.  
Animals were placed in supine position and fixed spread-eagled on a styrofoam block 
in a plastic tray. A skin incision was made over the abdominal cavity and the 
diaphragm was cut open along, to allow access to the rib cage. Then the sternum 
was removed carefully to expose the heart without cutting major vessels. While 
holding the still beating heart with forceps the needle of a syringe filled with 20 ml of 
cold PBS was placed in the left ventricle in a longitudinal orientation.             
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Following incision in the right atrium of the heart, PBS was injected with a steady 
pressure within 1 min into the left ventricle while blood was running out from the right 
atrium. The body was ‘cleared’ from blood when the color of the liver turned from 
dark red to bright red.  
 
2.2.4 In vitro experiments 
2.2.4.1 Preparation of mouse brain slices 
C57BL/6N mice, TG mice and WT littermates were sacrificed in deep inhalation 
anesthesia on day 1 or day 3 (only LysM-Cre+/-/IKK2fl/fl and LysM-Cre-/-/IKK2fl/fl mice) 
after MCAO. The skin was removed from the skull and the skull was then cut open in 
the middle. Following removal of the skullcap the brains were quickly taken out with a 
scoop and cut in three  2 mm thick coronal sections (Fig. 6) using a mouse brain 
slice matrix (Harvard Apparatus). 
 
 
2.2.4.2 Determination of infarct size 
Immediately after dissection brain slices were stained with 2% 2,3,5-
triphenyltetrazolium chloride (TTC) in polyphosphate buffered saline (PBS) for 10 min 
at room temperature to visualize the infarctions (Bederson et al., 1986b). In brief, the 
colorless redox-indicator TTC is enzymatically reduced to red formazan by 
dehydrogenases, which are abundantly arranged in the respiratory chain of the inner 
mitochondrial membrane. The staining intensity is well correlated with the amount of 
functional active mitochondria (Goldlust et al., 1996). 
Figure 6: PFA-fixed mouse brain (left). 
Three coronal sections of a mouse brain 
(right). 
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After scanning (Epson Perfection 3200 Photo) of the mouse brain slices, brain areas 
were traced and unstained areas were defined as ischemic lesions. Then the 
ipsilateral and contralateral hemispheric volumes of the three mouse brain slices 
were calculated by volumetry using the ImageJ software package (ImageJ software, 
National Institutes of Health, USA) as follows:  
Vdirect [mm3] = (area TTC section 1 [mm2] x 2.0 mm) + (area TTC section 2 [mm2] x 
2.0 mm) + (area TTC section 3 [mm2] x 2.0 mm).  
Afterwards infarctions were corrected for brain edema according to the following 
equation:  
Vindirect [mm3] = Vinfarct x (1-(VI – VC)/VC),  
whereas the term (VI – VC) represents the volume difference between the ischemic 
hemisphere and the control hemisphere and (VI – VC)/VC expresses this difference 
as a percentage of the control hemisphere (Ginsberg et al., 2003; Kleinschnitz et al., 
2011).  
 
2.2.4.3 Determination of blood-brain-barrier leakage with Evans blue  
To determine the permeability of the BBB to macromolecules the vascular tracer 
Evans blue is frequently used. Evans blue displays high affinity for the blood plasma 
protein albumin and upon i.v. injection, immediately binds to serum albumin, using it 
as its transporter protein. Following disruption of the BBB albumin-bound Evans blue 
crosses the BBB and penetrates the brain parenchyma. Evans blue can easily be 
detected macroscopically within the tissue due to its intensive blue color (Hamer et 
al., 2002). 
C57BL/6N mice treated with C1-INH (7.5 U or 15.0 U, respectively) or vehicle were 
i.v. injected with 100 µl of 2% Evans blue tracer diluted in 0.9% saline 1 hour after the 
induction of tMCAO (Belayev et al., 1996; Austinat et al., 2009). After 24 hours mice 
were sacrificed in deep anesthesia and brains were quickly removed and cut in 2 mm 
thick coronal sections as described above (2.2.4.1). Brain parenchyma stained by 
Evans blue was traced and volumetric measurements were performed using the 
ImageJ software package (ImageJ software, National Institutes of Health, USA) to 
estimate BBB damage. 
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2.2.4.4 Determination of brain edema formation 
To assess the extent of brain edema, C1-INH (7.5 U or 15 U, respectively)-treated 
mice or vehicle-treated Ctrl mice were sacrificed in deep anesthesia 24 hours after 
tMCAO. Brains were removed, hemispheres separated, and individually weighed to 
assess the wet weight (WW). Thereafter, the hemispheres were dried for 72 hours at 
60 °C (Incubator, Heraeus Function Line) and the dry weight (DW) was ascertained. 
Hemispheric water content (%) was calculated using the following formula:  
((WW-DW)/WW) x 100 (Austinat et al., 2009). 
 
2.2.4.5 Histology 
Preparation of cryo-sections from mouse brain slices 
TTC-stained native brain slices (2.2.4.2) or unstained PBS perfused brain slices 
(2.2.3) from C57BL/6N mice or Sn-/- and Sn+/+ mice were embedded planar in a 
Cryomould (disposable vinyl specimen molds, 4566, Sakuro) with Tissue Tec® and 
immediately frozen in liquid nitrogen (-196 °C). Then cryo-embedded brain slices 
were cut into 10 µm thick coronal sections using a microtome (Leika CM 1950) and fit 
to a glass slide. 
Hematoxylin/eosin (H&E) staining  
Brain cryo-sections were stained for 8 min with hematoxylin, followed by a 10 min 
washing step using running tap water and 20 sec staining with 0.05% eosin. Then 
dehydration of the sections was carried out using the following EtOH concentrations: 
3x 70%, 2x 96%, 2x 100%. Finally, sections were incubated twice in xylene for 3 min 
each and mounted onto an object plate with Vitro Cloud.  
 
2.2.4.6 Immunohistochemistry 
2.2.4.6.1 Immunoperoxidase staining 
Staining for neutrophils  
Brain sections were fixed in ice-cold acetone for 15 min at -20 °C.  
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Thereafter, epitopes were blocked by pretreatment with 10% of bovine serum 
albumin (BSA) in PBS for 45 min to prevent unspecific binding. For staining of 
invading neutrophils rat anti-mouse Ly-6B.2 alloantigen at a dilution of 1:1000 in PBS 
containing 1% BSA was added overnight at 4 °C. Afterwards, sections were 
incubated with a biotinylated rabbit anti-rat secondary antibody diluted 1:100 in PBS 
containing 1% BSA for 45 min at room temperature. Following 30 min treatment with 
Avidin/Biotin blocking solution to inhibit endogenous peroxidase activity, the 
secondary antibody was linked via streptavidin to a biotinylated peroxidase (POD) 
according to the manufacturer’s instructions for 35 min at room temperature. 
Antigens were visualized via POD using the chromogen 3,3`-diaminobenzidin (DAB). 
The reaction was stopped with ddH2O either when staining was observed or after 10 
min. After each step, slices were washed gently. Finally, sections were mounted onto 
an object plate with Aquatex (Austinat et al., 2009). Negative controls for all 
immunohistochemical experiments included omission of primary antibody which 
produced no signals (not shown). Tissue sections from murine spleens served as 
positive controls (not shown).  
Staining for macrophages/microglia 
Brain sections were fixed in 4% paraformaldehyde (PFA) in PBS at 4 °C for staining 
of macrophages/microglia. Epitope blocking was achieved with 5% BSA in PBS 
containing 0.2% Triton-X-100. Staining of infiltrating macrophages and activated 
microglia was performed overnight using rat anti-mouse CD11b at a dilution of 1:100 
in PBS containing 1% BSA as first antibody. The subsequent procedure was the 
same as for staining of neutrophils (Austinat et al., 2009). 
 
2.2.4.6.2 Immunofluorescence staining 
Staining for occludin 
Following 10 min fixation of the brain sections in 4% PFA in PBS for 
immunofluorescence staining against occluding, epitope blocking was achieved by 
incubation with a solution containing 1% BSA, 10% goat serum, 1% Tween®20 and 
0.3 M Glycine in PBS for 30 min. Thereafter, rabbit anti-mouse occludin antibody was 
applied overnight (4 °C) at a dilution of 1:100 in PBS containing 1% BSA.       
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Proteins were detected with Cy3-labeled goat anti-rabbit secondary antibodies and 
incubated at a dilution of 1:300 in 1% BSA in PBS at room temperature for 30 min. A 
fluorescent Hoechst dye was added for 15 min at a concentration of 0.4 mg/ml to 
stain the DNA. After each step, slices were washed gently. Finally, sections were 
mounted onto an object plate with Mowiol. Analysis of the sections was performed 
using a fluorescence microscope (Axiophot2; Carl Zeiss AG).  
Staining for fibrin(ogen) 
The staining procedure for fibrinogen was the same as for occludin except the 
blocking solution and the antibodies. Epitopes were blocked with 1% BSA in PBS 
containing 0.05% Triton-X-100 for 30 min at room temperature. The first antibody 
rabbit anti-mouse fibrinogen was applied at a dilution of 1:50 in 1% BSA in PBS 
overnight at 4 °C followed by incubation with the secondary antibody DyLight® 488 
goat anti-rabbit at a dilution of 1:300 in PBS containing 1% BSA for 30 min at room 
temperature. 
Double staining for sialoadhesin and macrophages/microglia 
For immunofluorescence double staining cryo-embedded brain sections were fixed in 
4% PFA in PBS for 10 min, followed by a 30 min epitope blocking step with PBS 
containing 5% BSA and 0.3% Triton-X-100. Detection of Sn was achieved with a rat 
anti-mouse CD169 antibody at a dilution of 1:300 in 1% BSA in PBS for 60 min at 
room temperature. Thereafter, brain slices were incubated with a goat anti-rat 
DyLight® 488 secondary antibody diluted 1:300 in PBS containing 1% BSA for 60 min 
at room temperature. Following treatment with Avidin/Biotin blocking solution a 
biotinylated primary antibody (rat anti-mouse CD11b) at a dilution of 1:100 in 1% 
BSA in PBS was applied for 60 min at room temperature to retrieve macrophages or 
activated microglia, respectively. Then sections were incubated with the fluorescent 
dye Cy3-labeled streptavidin at a dilution of 1:300 in PBS containing 1% BSA for     
45 min at room temperature. Stained brain sections were analysed using a 
fluorescence microscope (Axiophot2; Carl Zeiss AG). 
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2.2.4.7 Quantification of immune cell infiltrates 
Quantification of POD-detected immune cells was performed by selecting identical 
brain sections (thickness 10 µm) of ischemic hemispheres from C1-INH (7.5 U or 
15.0 U, respectively)-treated mice and vehicle-treated Ctrl mice. Cells were counted 
at a 40-fold magnification from 5 subsequent slices (distance 100 µm) from 4 
different animals under a Nikon microscope Eclipse 50i (Nikon GmbH) (Austinat.et 
al., 2009). 
 
2.2.4.8 Quantification of thrombotic brain vessels 
The whole brain was sliced 24 hours after tMCAO and H&E staining was performed 
as described above (2.2.4.5). Staining was examined in a blinded fashion under a 
microscope (Axiophot2; Carl Zeiss AG) equipped with a CCD camera (Visitron 
Systems). For calculation of the thrombosis index, the number of occluded blood 
vessels within the ischemic basal ganglia was counted in every 10th slice for vehicle-
treated Ctrl mice, or mice treated with 7.5 U or 15.0 U C1-INH, respectively, using a 
40-fold magnification. The quantification of occluded brain vessels was performed by 
Dr Kerstin Göbel from the laboratory of Prof Dr Wiendl, University Clinic, Münster. 
 
2.2.4.9 Polymerase chain reaction studies 
Polymerase chain reaction (PCR) studies were used to finally quantify the relative 
amount of mRNA transcripts present in brain tissue of mice at 24 hours after tMCAO. 
Processing for RNA isolation 
Brain slices from C57BL/6N mice (treated with vehicle or 7.5 U or 15.0 U C1-INH, 
respectively), Sn-/- mice and WT littermates, were divided into contralateral and 
ipsilateral hemispheres, and then into cortex and basal ganglia. Thereafter, brain 
samples were covered with TRIzol® Reagent and shock-frozen in liquid nitrogen       
(-196 °C). 
RNA isolation 
Brain tissue samples were homogenized in 1 ml of TRIzol® Reagent according to the 
manufacturer`s instructions using a Polytron®PT MR 2100 (Kinematica AG) 
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homogenizer at 30.000 rpm. Following incubation for 5 min at room temperature, the 
homogenized samples were mixed with 0.2 ml of chloroform and shook vigorously by 
hand for 15 sec and incubated for another 5 min. Then, samples were centrifuged 
(Eppendorf Centrifuge 54152) at 12.000 rpm for 15 min at 4 °C and the upper 
aqueous phase, containing the RNA was transferred to a fresh tube. Thereafter, RNA 
solution was mixed with 0.5 ml isopropyl alcohol and incubated at room temperature 
for 10 min. Following centrifugation at 12.000 rpm for 10 min at 4 °C, the supernatant 
was removed and the RNA precipitate was washed twice with 1 ml of 75% EtOH by 
vortexing. After a further centrifugation step at 7.500 rpm for 5 min at 4 °C the RNA 
pellet was air-dried for at least 15 min. Finally, total RNA was dissolved in 10-20 µl 
RNase-free DEPC water by passing the solution a few times through a pipette tip, 
and incubating it for 10 min at 56 °C. Total RNA concentration was measured 
spectrophotometrically (Eppendorf BioPhotometer) and quantified using the 
A260/A280 absorption. Samples of total RNA were stored at -80 °C (Austinat et al., 
2009). 
Reverse transcription (cDNA synthesis) of total RNA 
1 µg of total RNA was reverse transcribed to generate cDNA using the TaqMan® 
Reverse Transcription Reagents according to the manufacturer´s protocol. Thus, a 
mastermix was prepared (Tab. 7). Subsequently, the reaction tubes were each filled 
with 37.4 µl of mastermix, 1 µg of total RNA was pipetted and the tubes were refilled 
with DEPC water to the total volume of 60 µl per assay. Random Primer Hexamers 
were chosen for priming throughout the length of the RNA. All steps were performed 
wearing nitrile cloves, quickly and on ice to avoid RNase contamination. The reverse 
transcription was performed in a Labcycler (SensoQuest GmbH) according to the 
following incubation program: 10 min at 25 °C, 60 min at 42 °C and 5 min at 95 °C.  
 
Table 7: Pipette schema for preparation of the reverse transcription mastermix  
 
 
 
6 µl 10x RT-Buffer 
13.2 µl  MgCl2 (25 mM) 
12 µl  dNTP-Mix 
3 µl  Random-Hexamers 
1.2 µl  RNase-Inhibitor 
2 µl Reverse Transcriptase  
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Semiquantitative real time (RT-) PCR 
Semiquantitative RT-PCR was performed as previously described (Kleinschnitz et al., 
2004) with a total amount of 75 ng cDNA (as total input RNA) per assay to quantify 
relative gene expression levels of endothelin (Edn)-1, transforming growth factor 
(TGF)β-1, tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 with the 
fluorescent TaqMan® technology according to the manufacturer´s guidelines. 
Therefore, a mastermix was prepared (Tab. 8). 
For relative quantification of mRNA transcripts the PCR was normalized for the 
amount of RNA (applied to the reverse transcription) via an endogenous control, i.e. 
the constitutively expressed housekeeping gene glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). For calibration cDNA samples received from sham-
operated mice were applied and additionally, water controls were included to assure 
specificity and to exclude contamination. The real time PCR reactions with a total 
volume of 12.5 µl were run for 40 cycles using the following cycling conditions: 
50 ˚C for 2 min, 95 ˚C for 10 min, (95 ˚C for 15 sec, 60 °C for 1 min) x 40 cycles 
 
Table 8: Pipette scheme for mastermix for RT-PCR 
6.25 µl  TaqMan® Universal 2x PCR Master Mix 
0.625 µl  TaqMan® Predeveloped Assay Reagents for gene expression  
0.5 µl  DEPC water 
4.5 µl  cDNA sample 
 
Each sample was measured in triplicate using a Fast 96-Well Reaction Plate 
(MicroAmp; Applied Biosystems) and data sets were examined for integrity by 
analysis of the amplification plot. The comparative Ct method was used for the 
relative quantification of gene expression (Winer et al., 1999; Livak & Schmittgen, 
2001). Thereby 2–∆∆Ct gives the amount of target (Edn-1, TGFβ-1, TNF-α, IL-1β and 
IL-10), normalized to the endogenous control (GAPDH) and relative to a calibrator 
(cDNA from basal ganglia or cortices, respectively of sham-operated mice). Ct 
indicates the number of the cycle at which the fluorescence signal of the PCR 
product (the fluorescence signal is increased proportional to the amount of PCR 
product) exceeds a certain threshold, which was arbitrarily set within the exponential 
phase of the PCR.  ∆∆Ct was calculated by the following equation:  
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∆∆Ct = [(Cttarget (unknown sample) - Ctendogen control (unknown sample))] - [(Cttarget (calibrator sample) - 
Ctendogen control (calibrator sample))]  
 
2.2.4.10 Genotyping of mice 
Genomic DNA isolation from mouse tail 
Genomic DNA from Sn-/- mouse tails was purified using the DNeasy Blood & Tissue 
Kit 250 according to the guidelines of the manufacturer. 
Therefore, tail tips were cut and dissolved in 175 µL ATL-buffer (EDTA 
(ethylenediaminetetraacetic acid)-SDS (sodium dodecyl sulfate)-based lysis buffer) 
containing 20 µl Proteinase K by overnight incubation at 56 °C using a heating device 
(Eppendorf Thermomixer comfort) whilst shaking (1.000 rpm). Thereafter, an 
additional 200 µl AL-buffer (guanidine-based lysis buffer) was pipetted to each 
sample and mixed gently. After addition of 200 µl EtOH and mixed by inverting for a 
number of times, all of the sample was applied to a mini spin column and centrifuged 
at 8.000 rpm for 1 min. Mini spin columns were placed in a new collection tube, 500 
µl AW2 buffer (TRIS (tris(hydroxymethyl)-aminomethan)-based washing solution with 
EtOH) was added and mini spin columns were centrifuged for 3 min at 13.000 rpm. 
Then, collection tubes were replaced by fresh 2 ml reaction tubes. After adding 200 
µl AE buffer (TRIS-EDTA-based elution buffer), incubation for 1 min and a further 
centrifugation step for 1 min at 8.000 rpm AE buffer was collected containing the 
DNA and stored at 4 °C.  
Genotyping by PCR 
Genotypes of Sn-/- mice were determined by conventional PCR analysis in a total 
volume of 50 µl per assay using the following primer pairs: forward 5’ - CAC CAC 
GGT CAC TGT GAC AA - 3’ and reverse 5’ - GGC CAT ATG TAG GGT CGT CT - 3’. 
Therefore a mastermix was prepared (Tab. 9). Finally 1 µl of isolated genomic DNA 
of each mouse was added and PCR reaction was run using a special cycler program 
(Tab. 10). Afterwards amplificates were analyzed in an ethidium bromide (EtBr)-
stained 2% agarose gel in 1x TAE (TRIS base-acetic acid-EDTA) buffer, which 
resulted in the respected amplification size of 1729 bp for the TG Sn allele. 
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Table 9: Pipette scheme for Sn genotyping mastermix 
25.0 µl PCR Mastermix (2x) MaximaTM Hot Start Green 
0.25 µl forward primer (stock 100 µM) 
0.25 µl reverse primer (stock 100 µM) 
  2.5 µl DMSO 
21.0 µl DEPC-H2O                                                         
 
Table 10: Cycler program for genotyping of Sn-/- mice  
5 min 94 °C Hot start (initial denaturation) 
1 min 94 °C Denaturation 
1 min 61 °C Annealing 
2 min 72 °C Elongation 
5 min 72 °C Final extension 
Hold 10 °C  
 
 
2.2.4.11 Western blot analysis 
Western blot analysis was performed on protein lysates from ipsilateral and 
contralateral native basal ganglia and cortices from single mice to quantify the 
amount of fibrin(ogen) or occludin, respectively.  
Therefore, brain slices from vehicle-treated and C1-INH (7.5 U or 15.0 U, 
respectively)-treated C57BL/6N mice were dissected into ipsilateral and contralateral 
cortices and basal ganglia and brain tissue was immediately frozen in liquid nitrogen 
(-196 °C) and stored at -20 °C.  
Sample preparation and bicinchoninic acid (BCA) assay 
Native brain samples mixed with 120 µl RIPA buffer containing 0.1% sodium dodecyl 
sulfate (SDS) and 4% proteinase inhibitor in a 1.5 ml reaction tube were crumbled 
using a teflon pestle (Bel-Art products). Samples were sonified (Bandelin Sonopuls 
HD60) for 15 sec to further homogenize and centrifuged for 30 min at 13.200 rpm at 
4 °C. Afterwards, clear supernatants were quickly transferred to fresh reaction tubes 
and protein concentrations were measured using the BCA method. Different 
concentrations of BSA (0.05 mg/ml, 1.00 mg/ml, 2.50 mg/ml and 5.00 mg/ml) were 
used as standard. A mastermix composed of 1 ml BCA solution A + 20 µl Copper(II) 
40 cycles 
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sulphate solution B per assay was prepared. To 1 ml mastermix 2.5 µl protein sample 
or 5 µl BSA or 5 µl DEPC water as blank, respectively was added. Following 30 min 
incubation at 37 °C protein concentrations were measured spectrophotometrically 
(Eppendorf BioPhotometer).  
SDS-polyacrylamide gel electrophoresis (PAGE) 
Equal amounts of protein (20 µg) were taken for Western blot analyses. Samples 
were mixed with 2x sample loading buffer containing 20% β-mercaptoethanol and 
denaturated for 10 min at 95 °C. Protein separation was performed on a 12% SDS 
polyacrylamide gel according to Laemmli (1970) with a Bio-Rad Mini-Protean® 
TetraCell module (Bio-Rad Laboratories) and a power supplier (Power Pac Basic, 
Bio-Rad Laboratories). After SDS-PAGE proteins were transferred to an activated 
(with MeOH) polyvinylidene fluoride (PVDF, 0.45 µm, GE Health Care)  using a 
blotting chamber from PeqLab biotechnologies and a power supplier (Power Pac HC, 
Bio-Rad Laboratories GmbH) at 100 mA per gel for 1.5 hours.  
Immunoblotting 
After blocking for 30 min with a blocking buffer at room temperature to prevent 
unspecific antibody binding, membranes were incubated with the primary antibody on 
a shaking platform (Heidolph Duomax 1030) at 4 °C overnight with the following 
dilutions in blocking buffer: anti-fibrinogen pAb 1:500 or anti-occludin pAb 1:1000. 
After a washing step with TBST, membranes were incubated for 60 min with 
Horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG with gentle shaking 
at a dilution of 1:5000 at room temperature and were finally developed using ECLplus 
according to the manufacturer´s guidelines. Chemiluminescence was detected on 
medical X-Ray films (Fujifilm Super RX; Hartenstein) for several time points.  
Thereafter, membranes were incompletely stripped with 15% H2O2 in PBST for 30 
min at room temperature and blocked again. To detect the loading control anti-actin 
mAb diluted 1:75.000 in blocking buffer was used as primary antibody and retrieved 
with donkey anti-mouse IgG. Visualization was performed with ECLplus and X-Ray 
films (Kraft et al, 2010a). 
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2.2.5 Statistical analysis 
Mean values were reported as ± standard deviation (SD) and declared in the text, 
except for functional outcome scores, which were illustrated as scatter plots. The 
median with the 25% and 75% percentile was given in the text. Statistical analyses 
were performed using GraphPad Prism 5 (GraphPad software package). Data were 
tested for Gaussian distribution with the Kolmogorov-Smirnov test (with Dallal-
Wilkinson-Lillie for P value) and the D´Agostino and Pearson omnibus normality test. 
P < 0.05 was considered statistically significant. 
Results 
38 
 
3 RESULTS 
3.1 Assessment of the therapeutic effects of C1-inhibition in acute stroke in 
mice  
3.1.1 Infarct size and outcome after tMCAO following immediate application of 
C1-inhibitor 
Based on the fact that the contact-kinin system is activated during reperfusion the 
therapeutic potential of the human plasma derived C1-inhibitor (C1-INH) Berinert® P 
was tested under conditions of ischemia and reperfusion. Therefore, young adult 
male C57BL/6N mice were subjected to 1 hour of tMCAO and C1-INH was injected 
at a low dose of 7.5 units (U) and a high dose of 15.0 U per mouse 1 hour after onset 
of ischemia. Control (Ctrl) mice received equal amounts of vehicle (150 µl aqua ad 
injectabilia) instead of C1-INH. The therapeutic doses of C1-INH were chosen based 
on results of previous dose-finding studies (De Simoni et al., 2003, 2004). Twenty-
four hours after tMCAO infarct volumes were assessed by staining of the brain slices 
with 2% 2,3,5-triphenyltetrazolium chloride (TTC), a technique which is frequently 
used to distinguish macroscopically between ischemic and healthy (viable) tissue 
(Chiamulera et al., 1993; Hatfield et al., 1991).  
Mice treated with 15.0 U C1-INH displayed significantly reduced infarct sizes by 
approximately 60% compared with Ctrl mice, whereas the low dose of 7.5 U C1-INH 
did not change infarct volumes (mean 103.7 ± 27.2 mm3 [Ctrl] versus (vs.) 81.3 ± 
33.4 mm3 [7.5 U] or 40.4 ± 27.9 mm3 [15.0 U], respectively; P > 0.05 [Ctrl vs. 7.5 U] 
or P < 0.0001 [Ctrl vs. 15.0 U]) (Fig. 7).  
To investigate whether C1-INH treatment is also of functional relevance the global 
neurological function was assessed by the Bederson score (Bederson et al., 1986a) 
and the motor function and coordination by the grip test score (Moran et al., 1995). 
Mice treated with 15.0 U C1-INH displayed significantly better overall neurological 
function as well as improved motor function and coordination compared with Ctrl 
mice. The low dose of 7.5 U C1-INH failed to significantly ameliorate functional 
outcome (Fig. 7) indicating a dose-dependent effect of C1-INH in focal cerebral 
ischemia (Bederson score: median 3.0 [3.0, 3.75] [Ctrl] vs. 3.0 [2.5, 3.0] [7.5 U] vs. 
1.0 [0.75, 3.0] [15.0 U], respectively; P > 0.05 [Ctrl vs. 7.5 U] or P < 0.001 [Ctrl vs. 
15.0 U]) (Grip test score: median 3.0 [0.5, 3.75] [Ctrl] vs. 3.0 [3.0, 3.25] [7.5 U] vs. 4.0 
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[4.0, 5.0] [15.0 U], respectively; P > 0.05 [Ctrl vs. 7.5 U] or P < 0.001 [Ctrl vs.        
15.0 U]). 
 
Figure 7: A) Representative 2,3,5-triphenyltetrazolium chloride (TTC) staining of three 
corresponding coronal brain sections (upper panel) and infarct volumetry from the coronal brain 
sections of control mice (Ctrl) and mice treated with 7.5 U or 15.0 U C1-INH 1 hour post stroke on 
day 1 after tMCAO (lower panel) (n = 10-12/group). ***P < 0.0001, 1-way analysis of variance 
(ANOVA), Bonferroni post hoc test, 15.0 U group compared with Ctrl group. B) Neurological 
Bederson score (lower panel) and grip test score (upper panel) on day 1 after tMCAO of the 
groups indicated (n = 10-12/group). **P < 0.001, Kruskal-Wallis test followed by Dunn multiple 
comparison test, 15.0 U group compared with Ctrl group. 
 
3.1.2 Long-term outcome after immediate C1-inhibitor treatment 
First, the functional outcome and mortality over a period of one week after ischemic 
stroke was determined between C1-INH-treated and sham-operated animals. Until 
day 7 after tMCAO, 9 out of 10 Ctrl mice (90%) had died, which confirmed previous 
studies of our group (Austinat et al., 2009; Kleinschnitz et al., 2010b). In contrast, 
only one out of 10 mice (10%) following treatment with 15.0 U C1-INH had dies until 
day 7 after cerebral ischemia (P < 0.001). The effect of 7.5 U C1-INH was less 
pronounces in reducing mortality, but low dose treatment was still effective since only 
three out of 10 mice had died (P < 0.05) (Fig. 8).  
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In line with these findings, mice received 15.0 U C1-INH 1 hour after onset of 
ischemic stroke performed significantly better in the Bederson score and grip test 
score between day 1 and day 7 post tMCAO compared with Ctrl mice or mice treated 
with 7.5 U C1-INH (Bederson score: day 3: median 3.0 [3.0, 3.0] [Ctrl] vs. 1.0 [1.0, 
1.5] [7.5 U] or 1.0 [0.5, 1.0] [15.0 U], respectively; P < 0.001 [Ctrl vs. 7.5 U] and P < 
0.0001 [Ctrl vs. 15.0 U]; day 5: median 2.0 [2.0, 3.0] [Ctrl] vs. 1.0 [0.25, 1.0] [7.5 U] or 
0.0 [0.0, 1.0] [15.0 U], respectively; P < 0.001 [Ctrl vs. 15.0 U]) (grip test score: day 3: 
median 3.0 [2.0, 3.0] [Ctrl] vs. 3.5 [3.0, 4.0] [7.5 U] or 4.0 [4.0, 5.0] [15.0 U], 
respectively; P < 0.001 [Ctrl vs. 15.0 U]; day 5: median 3.0 [2.0, 3.0] [Ctrl] vs. 5.0 
[4.0, 5.0] [7.5 U] or 5.0 [4.0, 5.0] [15.0 U], respectively; P < 0.05 [Ctrl vs. 7.5 U] and  
P < 0.05 [Ctrl vs. 15.0 U]) (Fig. 9). These findings indicate a sustained neurological 
protection mediated by early applied high dose (15.0 U) of C1-INH, even at later 
stages of ischemia. 
 
Figure 8: A) Survival of control mice (Ctrl) and mice treated with 7.5 U or 15.0 U C1-INH 1 hour 
post stroke until day 7 after tMCAO (n = 10/group). **P < 0.001, *P < 0.05, log rank test, 7.5 U or 
15.0 U group, respectively compared with Ctrl group. B) Long-term neurological Bederson score 
(lower panel) and grip test score (upper panel). Figures show a selection of representative scores 
on day 3 and 5 after tMCAO of Ctrl mice and mice treated with 7.5 U or 15.0 U C1-INH 1 hour 
post stroke (n = 3-10/group). ***P < 0.0001, **P < 0.001, ##P < 0.001, #P < 0.05, Kruskal-Wallis 
test followed by Dunn multiple comparison test, 7.5 U or 15.0 U group, respectively compared 
with Ctrl group on day 3 (*) and day 5 (#), respectively. 
 
Results 
41 
 
Next, the safety profile of C1-INH treatment was tested by means of serial magnetic 
resonance imaging (MRI) on day 1 and 7 after ischemia to determine the dynamics of 
infarct development. 
Twenty-four hours after tMCAO MRI reaffirmed smaller infarctions in animals 
received 15.0 U C1-INH (day 1: mean 84.4 ± 26.1 mm3 [Ctrl] vs. 35.8 ± 19.2 mm3 
[15.0 U], respectively; P < 0.001; day 7: mean 42.5 ± 16.2 mm3 [Ctrl] vs. 16.4 ± 12.8 
mm3 [15.0 U], respectively; P < 0.05), compared with TTC assessed infarct sizes of 
mice treated in the same way. Importantly, follow-up MRI on day 7 after onset of 
ischemia demonstrated that infarct sizes in mice after 15.0 U C1-INH application did 
not increase between day 1 and 7 (P > 0.05), indicating a long-term neuroprotective 
effect in cerebral ischemia by high dose (15.0 U) C1-INH treatment (Fig. 9).    
 
Figure 9: A) Magnetic resonance imaging (MRI)-based infarct volumetry of control mice (Ctrl) or 
mice treated with 15.0 U C1-INH 1 hour post stroke on day 1 and 7 after tMCAO (n = 5-7/group). 
**P < 0.001, #P < 0.05, unpaired, two-tailed Student´s t-test, 15.0 U group compared with Ctrl 
group on day 1 (*) and day 7 (#), respectively. B) Representative panel of MRI pictures from Ctrl 
mice and mice treated with 15.0 U C1-INH. Ischemic lesions on serial coronal T2*weighted 
gradient-echo MR sequences are depicted as hypointense (bright) areas. 
 
The alleged reduction of infarct sizes on day 7 post stroke in treated and untreated 
animals (Fig. 9) was due to infarct maturation and subsequent fogging effects on 
MRI rather than true diminishment of infarction as described recently by Wagner et 
al. (2012). Importantly, infarcts always appeared hyperintense (bright) on T2*w MRI 
which represents a special sequence sensitive for intracerebral hemorrhage. 
Hypointense (dark) areas indicating intracerebral haemorrhage on T2*w MRI were 
always absent from C1-INH-treated mice as well as vehicle-treated Ctrl mice (Fig. 9). 
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This finding provides important safety data on C1-INH treatment early after infarction 
and at a more advanced stage of infarct development.  
To determine the effect of C1-INH concentrate on normal haemostasis in mice, a tail-
bleeding assay was performed with sham-operated mice. 15 min after injection of 
C1-INH (15.0 U) or vehicle, no differences in bleeding times could be detected 
between both groups (P > 0.05) (Fig. 10). 
  
 
3.1.3 Consequences of delayed application of C1-inhibitor on stroke outcome 
One critical issue in treatment of acute stroke patients is the narrow application 
window for thrombolysis with rt-PA, which is currently less than 4.5 hours after onset 
of stroke symptoms. Thus, treatments that can be given thereafter are eagerly 
awaited. 
In an attempt to widen the critical therapeutic window of exogenously applied        
C1-INH, mice were subjected to 1 hour of tMCAO and injected with C1-INH 6 hours 
after stroke onset. Neither treatment with low dose of 7.5 U C1-INH nor high dose of 
15.0 U C1-INH could reduce infarct sizes compared with vehicle-treated Ctrl mice 
(mean 102.5 ± 29.0 mm3 [Ctrl] vs. 102.4 ± 29.6 mm3 [7.5 U] or 94.7 ± 45.8 mm3 [15.0 
U], respectively; P > 0.05) (Fig. 11). 
In contrast, global neurological and motor-functional deficits of mice following 
delayed treatment with 15.0 U C1-INH were strongly reduced compared with Ctrl 
mice or mice treated with 7.5 U C1-INH 6 hours after tMCAO (Bederson score: 
median 3.0 [3.0, 3.75] [Ctrl] vs. 3.0 [2.5, 3.0] [7.5 U] or 2.0 [1.0, 3.0] [15.0 U], 
respectively; P < 0.001 [Ctrl vs. 15.0 U]; grip test score: median 3.0 [0.75, 4.0] [Ctrl] 
vs. 4.0 [3.0, 4.0] [7.5 U] or 5.0 [3.75, 5.0] [15.0 U], respectively; P < 0.001 [Ctrl vs. 
15.0 U]) (Fig. 11). This finding indicates that it is possible to improve outcome without 
affecting lesion size. 
Figure 10:  
Tail bleeding times of control mice (Ctrl) and 
15.0 U C1-INH-treated mice 15 min after 
injection of vehicle or C1-INH, respectively     
(n = 9/group). Not significant, P > 0.05, 
unpaired, two-tailed Students t-test.  
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Figure 11: A) Representative 2,3,5-triphenyltetrazolium chloride (TTC) staining of three 
corresponding coronal brain sections (upper panel) and infarct volumetry from the coronal brain 
sections on day 1 after tMCAO of control mice (Ctrl) and mice treated with 7.5 U or 15.0 U       
C1-INH 6 hours post stroke (lower panel) (n = 9-12/group). P > 0.05, 1-way ANOVA, Bonferroni 
post hoc test, C1-INH (7.5 U and 15.0 U)-treated mice compared with Ctrl mice. B) Neurological 
Bederson score (lower panel) and grip test score (upper panel) of Ctrl mice and mice treated with 
7.5 U or 15.0 U C1-INH 6 hours post stroke on day 1 after tMCAO (n = 9-12/group). **P < 0.001, 
Kruskal-Wallis test followed by Dunn multiple comparison test, 15.0 U group compared with Ctrl 
group. 
 
In order to assure, that beneficial effects of C1-INH did not result from insufficient 
occlusion of the origin of the MCA the regional CBF (rCBF) was monitored before 
surgery, 10 min after occlusion and again 10 min after reperfusion applying Laser-
Doppler flowmetry as described elsewhere (Dirnagl et al., 1989; Connolly et al., 
1996; Brede et al., 2011). The rCBF analysis was performed in our group and 
showed full occlusion of the MCA origin by dramatically reduced blood flow in the 
territory of the MCA in vehicle- and C1-INH (7.5 U or 15.0 U, respectively)-treated 
mice. Upon removal of the monofilament rCBF was almost fully restored (Fig. 12).  
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3.1.4 Effects of C1-inhibitor after permanent cerebral ischemia  
To investigate whether the therapeutic effects of C1-INH critically depend on 
reperfusion mice were challenged in the model of permanent occlusion of the MCA 
(pMCAO) and injected with C1-INH 1 hour after beginning of filament-induced 
occlusion.  
In contrast to the striking results of tMCAO studies, C1-INH in neither dose (7.5 U 
and 15.0 U) was able to reduce infarct sizes (mean 137.2 ± 12.2 mm3 [Ctrl] vs. 134.9 
± 44.2 mm3 [7.5 U] or 138.1 ± 23.5 mm3 [15.0 U], respectively; P > 0.05) (Fig. 13) or 
improve functional outcomes (Bederson score: median 3.0 [3.0, 4.0] [Ctrl] vs. 3.0 
[3.0, 4.0] [7.5 U] or 3.0 [2.0, 3.0] [15.0 U], respectively; P > 0.05; grip test score: 
median 2.0 [0.0, 3.0] [Ctrl] vs. 2.0 [0.0, 3.0] [7.5 U] or 3.0 [3.0, 4.0] [15.0 U], 
respectively; P > 0.05) (Fig. 13) on day 1 after pMCAO compared with vehicle-
treated Ctrl mice. This finding indicates a reperfusion-dependent effect of C1-INH in 
ischemic mice. 
 
3.1.5 Assessment of physiological parameters of mice treated with C1-inhibitor 
To exclude confounding effects on physiological parameters that by themselves may 
influence stroke development, additional studies to assess heart rate, blood pressure 
and blood gases in mice receiving vehicle or C1-INH immediately after injection were 
performed in cooperation with Dr Mark Brede, Department of Anaesthesiology, 
University of Würzburg. Effects of C1-INH in cardiovascular function were evaluated 
by invasive hemodynamic measurements (heart rate and blood pressure). 
Figure 12: Regional cerebral blood flow 
(rCBF) in the territory of the right middle 
cerebral artery (MCA) as measured by 
Laser Doppler flowmetry in vehicle-treated 
control mice (Ctrl) and mice treated with 
7.5 U or 15.0 U C1-INH (n = 3/group) at 
Baseline levels, after insertion of the 
filament (Ischemia) and again 10 min after 
removal of the filament (Reperfusion). No 
differences in rCBF were observed 
between the groups at any time point, 2-
way ANOVA, Bonferroni post hoc test, ns: 
not significant. 
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Figure 13: A) Representative 2,3,5-triphenyltetrazolium chloride (TTC) staining of three 
corresponding coronal brain sections (upper panel) and infarct volumetry from the coronal brain 
sections of control mice (Ctrl) and mice treated with 7.5 U or 15.0 U C1-INH 1 hour post stroke on 
day 1 after pMCAO (lower panel) (n = 7/group). P > 0.05, 1-way ANOVA, Bonferroni post hoc 
test, C1-INH (7.5 U and 15.0 U)-treated mice compared with Ctrl mice. B) Neurological Bederson 
score (lower panel) and grip test score (upper panel) on day 1 after pMCAO of the groups 
indicated (n = 7/group). P > 0.05, Kruskal-Wallis test followed by Dunn multiple comparison test, 
C1-INH (7.5 U and 15.0 U)-treated mice compared with Ctrl mice. 
 
Following application of 15.0 U C1-INH or vehicle, respectively, neither heart rate nor 
mean arterial blood pressure (Fig. 14) showed a significant difference between the 
groups (heart rate: mean 475.3 ± 36.2 min-1 [Ctrl] vs. 462.7 ± 12.4 min-1 [15.0 U], P > 
0.05; mean arterial blood pressure: 72.2 ± 6.5 mmHG [Ctrl] vs. 66.7 ± 5.6 mmHG 
[15.0 U], P > 0.05). These findings indicate that the clinically effective higher dose of 
15.0 U C1-INH in ischemic stroke does not affect cardiovascular function. Blood 
analysis for PaO2, PaCO2 and pH was performed with an arterial blood sample from 
the left cardiac ventricle and likewise revealed no significant differences between 
mice following injection with 15.0 U C1-INH or vehicle (Tab. 11). 
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Figure 14: A) Measurement of heart rate and B) mean arterial blood pressure in control mice 
(Ctrl) or mice after treatment with 15.0 U C1-INH (n = 4/group). Not significant, P > 0.05, 
unpaired, two-tailed Student´s t-test. 
 
Table 11: Results of blood gas analysis in vehicle-treated control mice (Ctrl) and mice that 
received 15.0 U C1-INH. ns, not significant, P > 0.05, unpaired, two-tailed Student´s t-test. 
 Ctrl 15.0 U P 
N 3 3  
PaO2 (mmHg) 67.1 ± 25.1 57.5 ± 6.2 ns 
PaCO2 (mmHg) 40.1 ± 18.9 42.5 ± 13.7 ns 
pH 7.3  ± 0.05 7.3 ± 0.10 ns 
 
3.2 Mechanisms of the therapeutic effects of C1-inhibitor on stroke outcome 
3.2.1 The permeability of the blood-brain-barrier after C1-inhibitor treatment 
Next, the effect of C1-INH on the patency of the blood-brain-barrier (BBB) after 
cerebral ischemia was examined. Therefore, the vascular tracer Evans blue was 
injected 1 hour after tMCAO, immediately after application of the C1-INH. The 
permeability of the BBB was assessed 24 hours after the procedure by means of 
volumetric measurements of the volume of Evans blue leakage into the brain 
parenchyma. 
The Evans blue extravasation in mice treated with 15.0 U C1-INH 1 hour after MCA 
occlusion was found significantly less compared with Ctrl mice. The low dose of 7.5 
U C1-INH showed only a small effect, but did not reach statistically significance 
(mean 51.6 ± 30.6 mm3 [Ctrl] vs. 33.1 ± 25.0 mm3 [7.5 U] or 13.9 ± 11.4 mm3 [15.0 
U], respectively; P < 0.001 [Ctrl vs. 15.0 U]) (Fig. 15). These findings indicate that 
15.0 U C1-INH provides sealing of the BBB during cerebral ischemia.  
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Accordingly, brain edema formation was attenuated following therapeutical 
application of 15.0 U C1-INH compared with Ctrl mice. In contrast, the low dose of 
7.5 U C1-INH failed to significantly reduce edema formation. Interestingly, there was 
no significant difference observable in brain edema between sham-operated mice 
and mice treated with 15.0 U C1-INH (mean 0.1 ± 1.3% [Sham] vs. 4.3 ± 1.1% [Ctrl] 
vs. 2.9 ± 1.0% [7.5 U] or 0.2 ± 1.0% [15.0 U], respectively; P < 0.0001 [Ctrl vs.     
15.0 U]; P < 0.0001 [Sham vs. Ctrl]; P < 0.001 [Sham vs. 7.5 U]) (Fig. 15). This 
finding is remarkable because in the 1 hour tMCAO model small infarcts always 
occur in the basal ganglia despite successful antithrombotic treatments (reviewed in 
Stoll et al., 2008). To evaluate the degree of brain swelling, the difference of the brain 
water content in the ipsilateral (ischemic) and contralateral (healthy) hemisphere on 
day 1 after tMCAO was determined using the wet/dry weight method (Austinat et al., 
2009). 
 
Figure 15: A) Brain edema formation as measured by the difference of brain water content in the 
ischemic and contralateral (healthy) hemisphere of sham-operated mice (Sham), control mice 
(Ctrl) and mice treated with 7.5 U or 15.0 U C1-INH, respectively, 1 hour post stroke on day 1 
after tMCAO (n = 5/group). ***P < 0.0001 and **P < 0.001 or ###P < 0.0001, respectively, 1-way 
ANOVA, Bonferroni post hoc test, (*) Sham group compared with Ctrl group and 7.5 U group or 
(#) Ctrl group compared with 15.0 U group, respectively. B) Representative corresponding coronal 
brain sections of Ctrl mice and mice treated with 7.5 U or 15.0 U C1-INH, respectively, 1 hour 
post stroke on day 1 after tMCAO after injection of the vascular tracer Evans blue (upper panel). 
Volume of Evans blue (EB) extravasation as determined by planimetry in the ischemic 
hemisphere of the indicated groups on day 1 after tMCAO (lower panel) (n = 7-10/group). **P < 
0.001, Kruskal-Wallis test followed by Dunn multiple comparison test, 15.0 U group compared 
with Ctrl group. 
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To test whether C1-INH counteracts BBB disruption and thereby brain edema 
formation when applied at a delayed setting, mice were treated with C1-INH 6 hours 
after onset of ischemic stroke. However, the leakage of i.v. injected Evans blue at 1 
hour after ischemia into the brain parenchyma did not significantly differ between  
C1-INH (7.5 U and 15.0 U)-treated mice and vehicle-treated Ctrl mice on day 1 after 
stroke (mean 44.6 ± 25.4 mm3 [Ctrl] vs. 37.3 ± 26.8 mm3 [7.5 U] or 14.9 ± 7.5 mm3 
[15.0 U], respectively; P > 0.05) (Fig. 16).  
 
Figure 16: A) Brain edema formation as measured by the difference of brain water content in the 
ischemic and contralateral (healthy) hemisphere of sham-operated mice (Sham), control mice 
(Ctrl) and mice treated with 7.5 U or 15.0 U C1-INH, respectively, 6 hours post stroke on day 1 
after tMCAO (n = 5/group). ***P < 0.0001, 1-way ANOVA, Bonferroni post hoc test, Sham group 
compared with Ctrl group, 7.5 U group and 15.0 U group, respectively. B) Representative 
corresponding coronal brain sections of Ctrl mice and mice treated with 7.5 U or 15.0 U C1-INH, 
respectively, 6 hours post stroke on day 1 after tMCAO upon injection of the vascular tracer 
Evans blue immediately after reperfusion (upper panel). Volume of Evans blue (EB) extravasation 
as determined by planimetry in the ischemic hemisphere of the indicated groups on day 1 after 
tMCAO (lower panel) (n = 5-6/group). P > 0.05, Kruskal-Wallis test followed by Dunn multiple 
comparison test, 15.0 U group compared with Ctrl group. 
 
Accordingly, C1-INH of neither dose was effective in limiting edema formation when 
injected 6 hours after tMCAO compared with sham-operated animals (mean 0.1 ± 
1.3% [Sham] vs. 4.3 ± 1.1% [Ctrl] or 4.6 ± 0.8% [7.5 U] or 3.9 ± 1.5% [15.0 U], 
respectively; P < 0.0001) (Fig. 16).  
A similar result was obtained for edema formation in the pMCAO model. Brain edema 
fully evolved within 24 hours after stroke in mice treated with C1-INH (7.5 U and   
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15.0 U) or vehicle (Ctrl) compared with sham-operated mice (mean 0.1 ± 1.4% 
[Sham] vs. 4.9 ± 1.4% [Ctrl] or 4.4 ± 1.5% [7.5 U] or 4.6 ± 1.8% [15.0 U], respectively; 
P < 0.001) (Fig. 17). 
 
 
3.2.2 Mechanisms of C1-inhibitor action on the blood-brain-barrier 
To assess the impact of C1-INH on the integrity of the BBB in mice on a molecular 
level the content of the tight junction protein occludin was quantified by Western blot 
analysis in ischemic brain lesions (Fig. 18). In ischemic basal ganglia of Ctrl mice the 
occludin expression was found strongly reduced, probably due to occludin 
degradation, whereas occludin expression was sustained in corresponding brain 
areas in mice treated with C1-INH (7.5 U and 15.0 U) (optical density: mean 0.08 ± 
0.11 AU (arbitrary units) [Ctrl] vs. 0.57 ± 0.31 AU [7.5 U] or 0.54 ± 0.15 AU [15.0 U], 
respectively; P < 0.05 [Ctrl vs. 7.5 U] and P < 0.05 [Ctrl vs. 15.0 U]) (Fig. 18). This 
indicates a BBB stabilizing effect mediated by C1-INH.  
Additionally, immunofluorescence staining was performed to further characterize the 
expression of occludin in ischemic brain capillaries. In accordance with the results 
obtained by Western blot analyses, occludin expression was preserved in vessels of 
C1-INH (15.0 U)-treated mice, but immunoreactivity was hardly detectable in vehicle-
treated Ctrl mice or mice treated with 7.5 U C1-INH (Fig. 19). 
Furthermore, the expression levels of endothelin (Edn)-1 in ischemic brains of Ctrl 
mice and mice treated with C1-INH was analyzed. Edn-1 is a vasoconstrictor peptide 
hormone that has been shown to be critically involved in the regulation of vascular 
integrity and edema formation under various pathophysiological conditions, including 
ischemic stroke (Matsuo et al., 2001; Lo et al., 2005). 
Figure 17: Brain edema formation as measured by 
the difference of brain water content in the ischemic 
and contralateral (healthy) hemisphere of sham-
operated mice (Sham), control mice (Ctrl) and mice 
treated with 7.5 U or 15.0 U C1-INH, respectively,    
1 hour after induction of stroke on day 1 after 
pMCAO (n = 5/group). **P < 0.001, 1-way ANOVA, 
Bonferroni post hoc test, Sham group compared with 
Ctrl group, 7.5 U group and 15.0 U group, 
respectively. 
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On day 1 after tMCAO relative mRNA expression levels of Edn-1 were detected by 
semiquantitative real time (RT-) PCR and assessed using the Ct method (Winer et 
al., 1999; Livak & Schmittgen, 2001). mRNA transcripts of Edn-1 were significantly 
elevated in the cortices and basal ganglia of vehicle-treated mice and mice receiving 
7.5 U C1-INH compared with sham-operated mice. In contrast, no significant 
induction of Edn-1 transcripts occurred in either brain region of mice after application 
of 15.0 U C1-INH (relative gene expression cortex: 1.0 ± 0.2 [Sham] vs. 16.0 ± 6.3 
[Ctrl] or 16.6 ± 6.8 [7.5 U] or 3.2 ± 3.0 [15.0 U], respectively; P < 0.0001 [Sham vs. 
Ctrl]; P < 0.0001 [Sham vs. 7.5 U]; P > 0.05) (Fig. 18), although the basal ganglia 
showed ischemic lesions in all animals. Compared with Ctrl mice no upregulation of 
relative Edn-1 expression levels was seen in cortices of mice after 15.0 U C1-INH 
application (P < 0.0001). 
 
Figure 18: A) Occludin expression in the ischemic basal ganglia on day 1 after tMCAO in control 
mice (Ctrl) or mice receiving 7.5 U or 15.0 U C1-INH 1 hour post stroke as determined by 
immunoblotting. Immunoblots against occludin and actin (loading control) with 4 animals of each 
group are shown. B) Densitometric quantification of occludin immunoreactivity of the indicated 
groups (n = 4/group). *P < 0.05, 1-way ANOVA, Bonferroni post hoc test, 7.5 U or 15.0 U group, 
respectively compared with Ctrl group. C) Relative gene expression of endothelin-1 (Edn-1) in the 
cortices and basal ganglia of sham-operated mice (Sham), vehicle-treated controls (Ctrl), and 
mice treated with 7.5 U or 15.0 U  C1-INH 1 hour post stroke on day 1 after tMCAO (n =             
6-14/group). ***P < 0.0001, +++P < 0.0001, 1-way ANOVA, Bonferroni post hoc test, 7.5 U group 
or 15.0 U group, respectively compared with Sham group (cortex (*)) or Ctrl group (cortex (+)), 
respectively). 
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Figure 19: Immunofluorescent detection of occludin expression (white arrows) on day 1 after 
tMCAO in the infarcted basal ganglia of control mice (Ctrl) or mice receiving 7.5 U or 15.0 U     
C1-INH, respectively, 1 hour post stroke. DAPI staining depicts cell nuclei. One representative 
panel per group is shown. 
 
3.2.3 Infiltration of immune cells from the circulation into the ischemic brain 
upon application of C1-inhibitor 
Ischemic brain lesions induce a profound secondary inflammatory response (Stoll et 
al., 1998). Therefore, the infiltration of immune cells into the ischemic brain lesions 
after C1-INH treatment was assessed. Immunoperoxidase staining against 
neutrophilic granulocytes (neutrophils) and activated microglia/macrophages was 
performed on mouse brains slices (Fig. 20) followed by quantification of invading 
immune cells into ischemic hemispheres on day 1 after induction of tMCAO. The 
amount of neutrophils as well as activated microglia and macrophages that have 
entered the ischemic brains of mice treated with 15.0 C1-INH 1 hour post stroke was 
found strongly reduced compared with Ctrl mice or mice treated with 7.5 U C1-INH. 
Here, the quantity of inflammatory macrophages/microglia and neutrophils was in 
accordance with previously published data (Gelderblom et al., 2009) (neutrophils: 
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mean 299.1 ± 138.1 [Ctrl] vs. 242.9 ± 87.0 [7.5 U] or 107.2 ± 109.5 [15.0 U], 
respectively; P < 0.05 [Ctrl vs. 15.0 U]; activated microglia/macrophages: mean 676.3 
± 150.4 [Ctrl] vs. 532.9 ± 29.5 [7.5 U] or 117.1 ± 65.0 [15.0 U], respectively; P < 
0.0001 [Ctrl vs. 15.0 U]) (Fig. 20). This finding indicates that application of 15.0 U 
C1-INH is accompanied with lower infiltration of leukocytes. 
 
Figure 20: A) Cellular inflammatory response in the ischemic basal ganglia of control mice (Ctrl) 
and mice treated with 7.5 U or 15.0 U C1-INH, respectively, 1 hour post stroke on day 1 after 
tMCAO. Quantification of immune cell infiltration (neutrophils; macrophages/microglia) of the 
groups indicated (n = 3-7/group). *P < 0.05, ###P < 0.0001, 1-way ANOVA, Bonferroni post hoc 
test, 15.0 U group compared with Ctrl group (neutrophilic granulocytes (*) or 
microglia/macrophages (#), respectively). B) Representative immunohistochemistry for 
neutrophils (anti-Ly-6B.2) or activated microglia/macrophages (CD11b).  
 
3.2.4 Expression levels of proinflammatory cytokines after C1-inhibitor 
treatment  
Inflammatory mediators have shown to be upregulated secondary to ischemic stroke 
and may lead to exacerbation of the injury (reviewed in Allan & Rothwell, 2001). 
Hence, the mRNA expression level of a series of cytokine genes was quantified by 
RT-PCR and the possible impact of exogenous applied C1-INH on the expression 
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profile was investigated. In the ischemic basal ganglia no significant induction of 
gene expression on day 1 after tMCAO following vehicle or C1-INH (7.5 U and     
15.0 U) treatment could be detected for the pro- and antiinflammatory cytokines 
interleukin (IL)-1β, tumor necrosis factor (TNF)-α, transforming growth factor (TGF)β-
1 and IL-10 compared with sham-operated mice (Tab. 12). 
 
Table 12: Results of relative gene expression levels of interleukin (IL)-1β, tumor necrosis factor 
(TNF)-α, transforming growth factor (TGF)β-1 and IL-10 in the cortices and basal ganglia of 
sham-operated mice (Sham), control mice (Ctrl) or mice treated with C1-INH (7.5 U or 15.0 U, 
respectively) obtained with RT-PCR; 1-way ANOVA following Bonferroni post hoc test, Ctrl mice 
or C1-INH-treated mice compared with Sham mice; ns: not significant (P > 0.05).  
Cytokine  
        Ischemic    
               area 
Group 
Cortex 
 
 
Basal ganglia 
 
 
 P  P 
IL-1β 
Sham 1.1 ± 0.1  1.3 ± 0.3  
Ctrl 77.7 ± 7.5 < 0.0001 24.4 ± 4.3 ns 
7.5 U 89.5 ± 11.7 < 0.0001 26.4 ± 4.1 ns 
15.0 U 32.1 ± 14.5 ns 22.9 ± 5.6 ns 
TNF-α 
Sham 1.1 ± 0.2  1.0 ± 0.3  
Ctrl 122.2 ± 8.6 < 0.0001 23.4 ± 2.6 ns 
7.5 U 109.9 ± 8.8 < 0.0001 29.3 ± 4.4 ns 
15.0 U 56.0 ± 15.0 < 0.0001 27.2 ± 3.0 ns 
TGFβ-1 
Sham 1.1 ± 0.1  1.1 ± 0.1  
Ctrl 6.6 ± 1.1 < 0.0001 1.9 ± 0.3 ns 
7.5 U 6.2 ± 0.7 < 0.0001 1.8 ± 0.4 ns 
15.0 U 3.8 ± 0.5 < 0.05 1.6 ± 0.2 ns 
IL-10 
Sham 1.3 ± 0.4  1.1 ± 0.2  
Ctrl 26.8 ± 4.7 < 0.0001 6.5 ± 1.0 ns 
7.5 U 27.2 ± 3.3 < 0.0001 6.6 ± 1.2 ns 
15.0 U 12.8 ± 3.1 ns 5.3 ± 0.8 ns 
 
In contrast, the expression levels of IL-1β transcripts (Fig. 21) in the infarcted 
cortices of vehicle-treated mice and mice receiving 7.5 U C1-INH 1 hour post stroke 
were found strongly elevated compared with the sham-operated group (Tab. 12)    
confirming previous investigations. Remarkably, no significant induction of IL-1β 
mRNA was found in cortices of mice following 15.0 U C1-INH application compared 
with the Sham group (Tab. 12). Hence, induction levels of IL-1β following treatment 
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with 15.0 U C1-INH were significantly reduced compared with IL-1β induction levels 
of the vehicle-treated group (P < 0.001). 
 
Figure 21: Relative gene expression of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, 
transforming growth factor (TGF)β-1 and IL-10 on day 1 after tMCAO or sham-operation in the 
cortices and basal ganglia of sham-operated mice (Sham), control mice (Ctrl) and mice treated 
with 7.5 U or 15.0 U C1-INH, respectively, 1 hour post stroke (n = 5-14/group). *P < 0.001, ***P < 
0.0001, ++P < 0.05, +++P < 0.001, 1-way ANOVA, Bonferroni post hoc test, 7.5 U or 15.0 U group, 
respectively compared with Sham group (cortex (*)) or Ctrl group (cortex (+)). 
 
For TNF-α expression in the ischemic cortices (Fig. 21) a strong induction in all 
groups could be detected compared with sham-operated mice (Tab. 12). However, 
TNF-α induction in mice treated with 15.0 U was attenuated compared with untreated 
mice following tMCAO (P < 0.0001). Ischemic stroke also led to a significant 
induction of TGFβ-1 expression (Fig. 21) in ischemic cortices of vehicle-treated mice 
and mice treated with 7.5 U or 15.0 U C1-INH, respectively compared with sham-
operated mice (Tab. 12). Again, expression of TGFβ-1 was significantly lower in mice 
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treated with 15.0 U C1-INH compared with Ctrl mice (P < 0.001). Significant 
upregulation of gene expression was also observed for IL-10 (Fig. 21) in mice treated 
with vehicle or 7.5 U C1-INH compared with sham-operated mice (Tab. 12). 
Induction of IL-10 was significantly reduced in mice following treatment with 15.0 U 
C1-INH (P < 0.001) compared with untreated Ctrl mice upon tMCAO. These findings 
suggest that efficacy of C1-INH secondary counteracts the synthesis of inflammatory 
cytokines probably due to smaller infarctions. 
 
Figure 22: A) Accumulation of fibrin(ogen) in the infarcted (i) and contralateral (c) cortices (upper 
panel) and basal ganglia (lower panel) of control mice (Ctrl) and mice treated with 7.5 U or 15.0 U 
C1-INH, respectively, 1 hour post stroke as determined by immunoblotting on day 1 after tMCAO. 
Immunoblots against fibrin(ogen) and actin (loading control) with two animals of each group (ipsi- 
and contralateral hemisphere) are shown. B) Densitometric quantification of fibrin(ogen) formation 
in the mouse groups and infarcted brain regions indicated (n = 4/group). **P < 0.0001, #P < 0.05, 
##P < 0.001, 1-way ANOVA, Bonferroni post hoc test, 7.5 U or 15.0 U group, respectively 
compared with Ctrl mice (cortex (*) or basal ganglia (#), respectively). 
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3.2.5 Microvascular thrombosis after treatment with C1-inhibitor 
To test whether fibrin formation in ischemic microvessels is affected by injection of 
C1-INH, the amount of fibrin(ogen) within basal ganglia and cortices of mice on day 1 
following ischemic stroke was quantified by Western blot analysis (Fig. 22).  
 
Figure 23: Immunofluorescent localization of fibrin(ogen) (white arrows) in the lumina of brain 
microvessels 1 day after tMCAO in the infarcted hemispheres of control mice (Ctrl) or mice 
treated with 7.5 U or 15.0 U C1-INH, respectively, 1 hour post stroke. DAPI staining depicts cell 
nuclei. One representative panel per group is shown. 
 
The levels of fibrin(ogen) in ischemic brains of vehicle-treated mice and mice treated 
with 7.5 U C1-INH 1 hour post stroke were dramatically elevated in comparison with 
both ischemic basal ganglia and cortices following application of 15.0 C1-INH (optical 
density cortex: mean 2.83 ± 1.08 AU [Ctrl] vs. 1.74 ± 0.79 AU [7.5 U] or 0.03 ± 0.02 
AU [15.0 U], respectively; P < 0.001 [Ctrl vs. 15.0 U]; optical density basal ganglia: 
mean 2.76 ± 1.00 AU [Ctrl] vs. 1.20 ± 0.68 AU [7.5 U] or 0.28 ± 0.15 AU [15.0 U], 
respectively; P < 0.05 [Ctrl vs. 7.5 U]; P < 0.001 [Ctrl vs. 15.0 U]) (Fig. 22). 
Compared with contralateral (c) hemispheres there was no clear difference of 
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fibrin(ogen) detectable in ipsilateral (i) sides in the 15.0 U C1-INH treatment group, 
whereas the fibrin(ogen) levels between ipsi- and contralateral sides in both other 
groups (Ctrl and 7.5 U C1-INH) highly differed.  
The results obtained by immunoblot analysis could be validated by 
immunofluorescence staining (Fig. 23) demonstrating less fibrin(ogen) deposits in 
ischemic brain capillaries of mice treated with 15.0 C1-INH.  
 
Figure 24: Representative hematoxylin/eosin (H&E) staining from the infarcted basal ganglia of 
control mice (Ctrl) and mice treated with 15.0 U C1-INH 1 hour after onset of ischemia on day 1 
after tMCAO (upper panel). Thrombotic vessels are indicated by arrows and patent vessel by 
arrowheads. Amount of occluded vessels in the infarcted basal ganglia of control mice (Ctrl) and 
mice treated with 7.5 U or 15.0 U C1-INH, respectively, 1 hour post stroke on day 1 after tMCAO 
as assessed by the thrombosis index (lower panel) (n = 5/group). *P < 0.05, 1-way ANOVA, 
Bonferroni post hoc test, 15.0 U group compared with Ctrl group. 
 
In accordance with those findings, histological H&E stainings of infarcted brain tissue 
sections from vehicle-treated Ctrl mice showed numerous occlusions of vessel 
lumina. In comparison, the rate of microvascular patency in corresponding brain 
areas of mice treated with the high-dose of C1-INH (15.0 U) was significantly 
increased (thrombosis index for occluded vessels: mean 15.8 ± 3.0 [Ctrl] vs. 12.2 ± 
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2.8 [7.5 U] or 9.8 ± 2.4 [15.0 U], respectively; P < 0.05 [Ctrl vs. 15.0 U]) (Fig. 24).  
This experiment was performed in cooperation with Dr Kerstin Goebel from the 
neurological university clinic, Münster. 
 
Figure 25: A) Formation of fibrin(ogen) in the ischemic cortices (upper panel) and basal ganglia 
(lower panel) of control mice (Ctrl) and mice treated with 7.5 U or 15.0 U C1-INH, respectively,    
6 hours post stroke as determined by immunoblotting on day 1 after tMCAO. Immunoblots 
against fibrin(ogen) and actin (loading control) with 4 animals of each group are shown.              
B) Densitometric quantification of fibrin(ogen) accumulation in the groups and infarcted brain 
regions indicated (n = 4-5/group). P > 0.05, 1-way ANOVA, Bonferroni post hoc test, C1-INH   
(7.5 U and 15.0 U)-treated mice compared with Ctrl mice. 
 
Additionally, immunoblot analysis against fibrin(ogen) was performed in mice treated 
with C1-INH 6 hours post tMCAO and in mice injected with C1-INH 1 hour after the 
onset of permanent ischemia. As it was already observed for edema formation,     
C1-INH, when applied in a delayed setting (Fig. 25) or in the model of pMCAO (Fig. 
26), was not able to prevent fibrin accumulation compared with vehicle-treated Ctrl 
animals (C1-INH 6 hours post stroke: optical density cortex: mean 2.92 ± 0.82 AU 
[Ctrl] vs. 3.20 ± 0.40 AU [7.5 U] or 3.48 ± 0.90 AU [15.0 U], respectively; P > 0.05; 
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optical density basal ganglia: mean 3.88 ± 0.94 AU [Ctrl] vs. 5.10 ± 0.66 AU [7.5 U] or 
3.41 ± 1.32 AU [15.0 U], respectively; P > 0.05) (pMCAO: optical density cortex: 
mean 4.07 ± 0.48 AU [Ctrl] vs. 3.85 ± 0.75 AU [7.5 U] or 3.31 ± 0.43 AU [15.0 U], 
respectively; P > 0.05; optical density basal ganglia: mean 3.55 ± 0.79 AU [Ctrl] vs. 
3.33 ± 0.36 AU [7.5 U] or 3.98 ± 0.97 AU [15.0 U], respectively; P > 0.05). These 
results are indicative for an interference of C1-INH with microvascular thrombosis 
under conditions of reperfusion and when applied early after ischemic brain injury.  
 
Figure 26: A) Fibrin(ogen) formation in the ischemic cortices (upper panel) and basal ganglia 
(lower panel) of control mice (Ctrl) and mice treated with 7.5 U or 15.0 U C1-INH 1 hour post 
stroke as determined by immunoblotting on day 1 after pMCAO. Immunoblots against fibrin(ogen) 
and actin (loading control) with 4 animals of each group are shown. B) Densitometric 
quantification of fibrin(ogen) generation in the groups and infarcted brain regions indicated (n =    
4-5/group). P > 0.05, 1-way ANOVA, Bonferroni post hoc test, C1-INH-treated mice compared 
with Ctrl mice. 
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3.3 The role of macrophage-specific adhesion molecule sialoadhesin in the 
pathogenesis of cerebral ischemia 
Disturbance of the BBB in ischemic stroke is accompanied by microglia activation 
and secondary recruitment of inflammatory cells into the brain parenchyma (Stoll et 
al., 1998). The perivascular space is populated by a special cell type of monocyte 
origin, the perivascular macrophage, characterized by the expression of the ED2 
marker in rats (Stoll & Jander, 1999). Perivascular macrophages, moreover, express 
the adhesion molecule sialoadhesin (Sn) in rodents and are located at the interface 
between cerebral endothelial cells and the brain parenchyma. Sn is restricted to 
macrophage-like cells (Crocker et al., 1994) in rodents. This study took advantage of 
Sn-/- mice to address the role of Sn in breakdown of the BBB and lesion development 
during focal cerebral ischemia. 
 
3.3.1 Sialoadhesin expression after cerebral ischemia in normal mice 
In a first step, the expression of Sn was investigated by immunohistochemistry under 
healthy conditions in 8-12 weeks old sham-operated WT mice (Sn+/+). Sn was not 
detectable within normal brain parenchyma, but strongly expressed on cells located 
around vessels, most likely presenting perivascular macrophages (Fig. 27), as 
reported before (Hartnell et al., 2001). Moreover, Sn expression within ischemic 
hemispheres was dramatically increased in Sn+/+ mice in the first 24 hours after 
tMCAO (mean 970.3 ± 70.8) (Fig. 27), where no signal could be detected prior to the 
insult (compared with sham-operated Sn+/+ mice).  
In order to identify the cellular origin of Sn expression, immunofluorescence double 
staining against Sn (CD169, specific marker for Sn) and macrophage-like cells 
(CD11b, specific marker for macrophages/microglia) was performed on brain 
sections of Sn+/+ mice. CD11b+ microglia showed a strong staining for CD169 in 
ischemic hemispheres of Sn+/+ mice 24 hours after tMCAO (Fig. 27). 
 
3.3.2 Stroke development in sialoadhesin deficient mice 
Since Sn was constitutively expressed on perivascular macrophages in sham-
operated Sn+/+ mice and further induced in microglial cells within 24 hours after 
tMCAO (Fig. 27) the functional role of Sn in stroke development was addressed 
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using a constitutive full knock-out mouse strain lacking Sn on macrophage-like cells 
(Sn-/- mice). As expected, immunohistochemistry on day 1 using CD 169 could not 
detect Sn in coeval Sn-/- littermates following 1 hour of tMCAO, neither in ischemic 
nor in healthy brain hemispheres (Fig. 27). 
 
Figure 27: A) Representative immunofluorescence double stainings of microglia/macrophages 
(CD11b) (red) and sialoadhesin (CD169) (green) in the ischemic hemispheres of sialoadhesin 
expressing (Sn+/+) mice on day 1 after tMCAO. B) Representative immunoperoxidase stainings of 
sialoadhesin (CD169) in the ipsilateral hemisphere of Sn+/+ mice 24 hours after sham-operation 
(Sham) and in the ipsilateral (ischemic) hemisphere of Sn+/+ and Sn-/- (sialoadhesin deficient) 
mice 24 hours after stroke induction. 
 
Infarct volumes in Sn-/- and Sn+/+ mice were assessed by the TTC method for vital 
tissue staining on day 1 after onset of ischemia. The results revealed only a slight 
reduction of infarct size in Sn-/- mice compared with WT littermates (mean 102.4 ± 
28.1 mm3 [Sn+/+] vs. 84.5 ± 15.6 mm3 [Sn-/-], P > 0.05), but did not reach statistical 
significance (Fig. 28). Surprisingly, mice deficient for Sn showed significantly less 
severe neurological dysfunction (Bederson scores: median 3.0 (3.0, 4.25) [Sn+/+] vs. 
2.0 (1.0, 3.0) [Sn-/-], P < 0.001) and less deficits in motor function and coordination 
(grip test score: median 3.0 (0.0, 4.0) [Sn+/+] vs. 4.0 (3.75, 5.0) [Sn-/-], P < 0.05) 
despite normal infarct volumes compared with the WT (Sn+/+) group (Fig. 28). 
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To assess the consequences of Sn deficiency on subacute stroke development non-
invasive serial MRI measurements was performed in living mice. Infarct lesions were 
already well demarcated on T2*w gradient-echo images on day 1 and the extent of 
infarction did not change over the next few days in both WT and Sn-/- mice (day 1: 
mean 104.2 ± 38.2 mm3 [Sn+/+] vs. 77.7 ± 10.4 mm3 [Sn-/-], P > 0.05; day 3: mean 
102.5 ± 42.6 mm3 [Sn+/+] vs. 67.2 ± 22.8 mm3 [Sn-/-], P > 0.05) (Fig. 29). 
 
Figure 28: A) Representative 2,3,5-triphenyltetrazolium chloride (TTC) staining of three 
corresponding coronal brain sections (upper panel) and infarct volumetry from the coronal brain 
sections of sialoadhesin deficient (Sn-/-) mice and WT littermates (Sn+/+) on day 1 after tMCAO 
(lower panel) (n = 10/group). P > 0.05, unpaired, two-tailed Student´s t-test. B) Neurological 
Bederson score (lower panel) and grip test score (upper panel) of the indicated groups on day 1 
after tMCAO (n = 10/group). *P < 0.05, **P < 0.001, two-tailed Mann Whitney-test. 
 
Moreover, MRI on day 1 reaffirmed similar infarct sizes in Sn-/- and Sn+/+ mice, as 
obtained by the TTC method, with a tendency of smaller infarctions in Sn-/- animals. 
As it was already shown before (Fig. 28), Sn-/- mice performed significantly better on 
both days after tMCAO compared with WT littermates (Bederson score: day 1: 
median 4.0 (3.0, 4.0) [Sn+/+] vs. 2.0 (1.0, 3.0) [Sn-/-], P < 0.05; day 3: median 3.0 (2.5, 
3.5) [Sn+/+] vs. 1.5 (1.0, 2.25) [Sn-/-], P < 0.05; grip test score: day 1: median 3.0 (0.5, 
3.5) [Sn+/+] vs. 4.0 (3.75, 5.0) [Sn-/-], P < 0.05; day 3: median 3.0 (2.0, 4.0) [Sn+/+] vs. 
5.0 (3.75, 5.0) [Sn-/-], P < 0.05) (Fig. 29). 
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Given the important role of macrophages in preventing intracerebral bleeding after 
stroke (Gliem et al., 2012), the bleeding tendency in Sn-/- mice after stroke was 
further assessed using iron-sensitive T2*w MR sequences. Sn deficiency did not 
induce intracerebral hemorrhage since ischemic lesions always appeared 
hyperintense (bright) (Fig. 29). These findings demonstrate that Sn deficiency in 
mice is not associated with secondary infarct growth, delayed deterioration of 
functional outcome, or bleeding complications. 
 
Figure 29: A) Representative panel of magnetic resonance imaging (MRI) from sialoadhesin 
deficient (Sn-/-) mice and WT littermates (Sn+/+ mice) on day 1 and day 3 after tMCAO (upper 
panel). Ischemic lesions on serial coronal T2*weighted gradient-echo MR sequences are 
depicted as hypointense (bright) areas. MRI–based infarct volumetry of the groups indicated on 
day 1 and day 3 after tMCAO (lower panel) (n = 5-6/group). P > 0.05, unpaired, two-tailed 
Student´s t-test, Sn+/+ compared with Sn-/- on day 1 or day 3, respectively. B) Neurological 
Bederson score (lower panel) and grip test score (upper panel) of the indicated groups on day 1 
and day 3 after tMCAO (n = 5-6/group). *P < 0.05, #P < 0.05, two-tailed Mann Whitney-test, Sn+/+ 
compared with Sn-/- (day 1 (*) or day 3 (#)). 
 
3.4 Functional consequences of sialoadhesin deficiency on blood-brain-barrier 
integrity and inflammation 
To assess the integrity of the BBB following 1 hour of tMCAO in Sn-/- mice 
extravasation of Evans blue into the brain parenchyma was analyzed on day 1. 
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Therefore, mice were i.v. injected with 100 µl Evans blue immediately after removal 
of the filament (1 hour after induction of ischemia). Twenty-four hours after stroke 
Sn+/+ mice displayed huge extravasation of the vascular tracer into the brain 
parenchyma compared with sham-operated WT littermates, indicating lost integrity of 
the BBB in Sn+/+ mice after cerebral ischemia. Importantly, in Sn-/- mice the 
extravasation of Evans blue into the brain parenchyma did not reach statistical 
significance compared with sham-operated mice (mean 1.3 ± 0.1 mm3 [Sham] vs. 
93.5 ± 12.5 mm3 [Sn+/+] or 56.7 ± 25.7 mm3 [Sn-/-], respectively; P < 0.05 [Sham vs. 
Sn+/+] and P > 0.05 [Sham vs. Sn-/-]) (Fig. 30). This finding provides evidence that Sn 
deficiency counteracts disruption of the BBB. 
 
 
 
To elucidate whether the improved functional outcome of Sn-/- mice after tMCAO was 
due to reduced microglia activation immunoperoxidase staining against CD11b was 
performed. Under healthy conditions CD11b was not detectable in brain parenchyma 
of WT mice (data not shown). On day 1 after onset of ischemia the number of 
CD11b+ cells in ischemic hemispheres of Sn-/- mice was remarkably reduced by more 
than 50% compared with Sn+/+ mice (mean 744.7 ± 129.8 [Sn+/+] vs. 299.8 ± 94.5  
[Sn-/-], P < 0.0001) (Fig. 31). A similar result was obtained for contralateral 
hemispheres, with a significant reduction in the number of cells stained positive for 
CD11b in Sn-/- mice compared with WT littermates (mean 394.5 ± 123.2 [Sn+/+] vs. 
80.9 ± 40.8 [Sn-/-], P < 0.0001) (Fig. 31). These findings demonstrate that Sn 
Figure 30: Representative corresponding 
coronal brain sections of sialoadhesin expressing 
(Sn+/+) sham-operated mice (Sham), Sn+/+ mice 
and Sn-/- mice after injection of Evans blue at 1 
hour after stroke onset on day 1 (upper panel). 
Volume of Evans blue (EB) extravasation as 
determined by planimetry in the ischemic 
hemisphere of the indicated groups on day 1 
after tMCAO (lower panel) (n = 3/group). *P < 
0.05, Kruskal-Wallis test followed by Dunn 
multiple comparison test, Sham group compared 
with Sn+/+ group. 
Results 
65 
 
deficiency is accompanied with a reduced activation of macrophages/microglia 
(CD11b+) in ischemic lesions. 
 
Figure 31: A) Representative immunoperoxidase stainings for activated microglia/macrophages 
(CD11b+ cells) in ischemic hemispheres of sialoadhesin deficient (Sn-/-) mice and WT littermates 
(Sn-/- mice) on day 1 after tMCAO. Arrowheads indicate cells with a macrophage-like morphology 
(rounded cell body without branches); arrows indicate cells with a microglia-like morphology 
(small cell body with several branches). B) Cellular inflammatory response in ischemic and 
contralateral (healthy) hemispheres of Sn-/- and Sn+/+ mice on day 1 after tMCAO. Quantification 
of immune cell infiltration (microglia/macrophages) in the indicated groups as assessed by 
immunohistochemistry (n = 4-6/group). ***P < 0.0001, ###P < 0.0001, unpaired, two-tailed 
Student´s t-test, compared with the respective control (ischemic hemisphere (*) or contralateral 
hemisphere (#)). 
 
As macrophages/microglia are an important source of proinflammatory cytokines, the 
expression profiles of the proinflammatory cytokines interleukin (IL)-1β and tumor 
necrosis factor (TNF)-α in the ischemic lesions of Sn+/+ and Sn-/- mice were assessed 
by RT-PCR (Fig. 32). 
Twenty-four hours after tMCAO IL-1β and TNF-α transcript levels in ischemic cortices 
of both Sn+/+ and Sn-/- mice were significantly increased compared with sham-
operated WT littermates (IL-1β: mean 0.8 ± 0.3 [Sham] vs. 88.0 ± 19.4 [Sn+/+] or 
104.5 ± 57.4 [Sn-/-], respectively; P < 0.0001 [Sham vs. Sn+/+] and P < 0.0001 [Sham 
vs. Sn-/-]; TNF-α: mean 0.1 ± 0.5 [Sham] vs. 103.3 ± 27.3 [Sn+/+] or 93.8 ± 31.2 [Sn-/-], 
respectively; P < 0.0001 [Sham vs. Sn+/+] and P < 0.0001 [Sham vs. Sn-/-]), whereas 
there was no significant difference between Sn+/+ and Sn-/- mice (P > 0.05) (Fig. 32). 
In contrast, no significant upregulation was seen in the ischemic basal ganglia (IL-1β: 
mean 0.1 ± 0.5 [Sham] vs. 16.6 ± 6.0 [Sn+/+] or 34.3 ± 16.2 [Sn-/-], respectively; P > 
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0.05; TNF-α: mean 1.2 ± 0.3 [Sham] vs. 15.3 ± 5.8 [Sn+/+] or 26.0 ± 16.3 [Sn-/-], 
respectively; P > 0.05) (Fig. 32).  
These findings demonstrate that absence of Sn from activated 
microglia/macrophages does not influence cytokine induction in the ischemic brain, 
although the expression of the microglia/macrophage surface marker CD11b was 
reduced. 
 
Figure 32: Relative gene expression levels of interleukin (IL)-1β and tumor necrosis factor (TNF)-
α in the ischemic cortices and basal ganglia of sialoadhesin expressing (Sn+/+) sham-operated 
mice (Sham) and of sialoadhesin deficient (Sn-/-) mice and WT littermates (Sn+/+) on day 1 after 
tMCAO (n = 3-8/group). ***P < 0.0001, 1-way ANOVA, Bonferroni post hoc test, Sham mice 
compared with Sn+/+ or Sn-/- mice, respectively, in respective brain areas; ns: not significant. 
 
3.5 Stroke development in mice defective in macrophage-specific nuclear 
factor-kappa B activation 
To gain further insight into the contribution of macrophages to stroke development 
tMCAO was induced in conditional knock-out mice (LysM-Cre+/-/IKK2fl/fl) displaying a 
non-functional transcription factor nuclear factor (NF)-ϰB within the myeloid cell 
lineage, including macrophages and microglia (Kanters et al., 2003). NF-ϰB regulates 
transcription of proinflammatory signaling molecules such as the proinflammatory 
cytokines IL-1β and TNF-α, but also chemokines and cell adhesion molecules such 
as ICAM-1 (Pahl, 1999; Fujihara et al., 2000). Hence, macrophages of LysM-Cre+/-
/IKK2fl/fl mice are not able to completely develop their immunological function and 
thus, represent an ideal target to investigate the hypothesis that macrophages induce 
tissue damage upon cerebral ischemia.  
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To address the question whether non-functional NF-ϰB in macrophages/microglia 
plays a role in ischemic stroke LysM-Cre+/-/IKK2fl/fl mice underwent 1 hour of tMCAO 
followed by evaluation 24 hours after stroke.  
Similar to Sn-/- mice, lesions of LysM-Cre+/-/IKK2fl/fl mice as assessed by the TTC 
method displayed no significant difference in size compared with the WT littermates 
(LysM-Cre-/-/IKK2fl/fl mice) (mean 90.6 ± 37.0 [LysM-Cre-/-/IKK2fl/fl] vs. 106.3 ± 25.1 
[LysM-Cre+/-/IKK2fl/fl], P > 0.05) (Fig. 33). However, compared with observations 
made in Sn-/- mice, neurological and motor-functional deficits had not improved in the 
LysM-Cre+/-/IKK2fl/fl mice compared with the WT group (Bederson score: median  3.0 
(1.0, 3.0) [LysM-Cre-/-/IKK2fl/fl] vs. 3.0 (2.0, 3.0) [LysM-Cre+/-/IKK2fl/fl], P > 0.05; grip 
test score: median 4.0 (3.0, 4.0) [LysM-Cre-/-/IKK2fl/fl] vs 3.0 (3.0, 4.0) [LysM-Cre+/-
/IKK2fl/fl], P > 0.05) (Fig. 33). These findings demonstrate that NF-ϰB activation in 
macrophages/microglia does not contribute to tissue damage and deteriorated 
neurological outcome within the first 24 hours after focal cerebral ischemia. 
 
Figure 33: A) Representative 2,3,5-triphenyltetrazolium chloride (TTC) staining of three 
corresponding coronal brain sections (upper panel) and infarct volumetry from coronal brain 
sections of LysM-Cre-/-/IKK2fl/fl and LysM-Cre+/-/IKK2fl/fl mice on day 1 after tMCAO (lower panel) 
(n=7/group). P > 0.05, unpaired, two-tailed Student´s t-test. B) Neurological Bederson score 
(lower panel) and grip test score (upper panel) on day 1 after tMCAO of the indicated groups (n = 
7/group). P > 0.05, two-tailed Mann Whitney-test. 
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4 DISCUSSION 
To date, i.v. thrombolysis with rt-PA to resolve vessel occluding clots is the only 
therapy approved for acute ischemic stroke in humans (NINDS, 1995). However, the 
effects on clinical outcome are modest and dependent on time. Within 0-90 min one 
out of 4.5 patients benefit from rt-PA treatment. Between 90-180 min 9 patients 
require treatment for a favorable outcome in one and at 180-270 min after stroke 
onset it reaches 14 patients to be treated for one satisfying result. This may partly be 
due to treatment failure in thrombolysis and reopening of the occluded vessels, but 
even studies with additional mechanical thrombectomy which revealed higher 
recanalization rates so far did not improve outcome at a statistically significant level 
(Chimowitz, 2013). Obviously, reperfusion of ischemic brain tissue is mandatory for 
clinical recovery after stroke, but does not guarantee a good outcome which is due to 
a process named ischemia/reperfusion (I/R) injury in the literature. This also applies 
to other organ systems such as heart or lung (Farb et al., 1993; de Perrot et al., 
2003). The mechanisms underlying I/R injury are largely unknown. 
The present thesis focused on the role of natural inhibitor C1-inhibitor (C1-INH) 
Berinert® P in I/R injury in focal cerebral ischemia in young adult mice. The efficacy of 
C1-INH has been determined using different doses, time points of application and the 
experimental stroke models of transient (tMCAO) and permanent MCA occlusion 
(pMCAO). The second part of the thesis addressed the macrophage-specific role in 
stroke development using two different genetic mouse models deficient for the 
adhesion molecule sialoadhesin (Sn) and the transcription factor nuclear factor (NF)-
ϰB, respectively.  
 
4.1 Human plasma derived C1-inhibitor protects from ischemic brain damage in 
clinically relevant scenarios 
In the present murine stroke study the efficacy of human plasma derived C1-INH in 
experimental stroke was addressed. Fundamental, the results revealed that C1-INH 
acts in a dose-dependent manner and that high dose of 15.0 U C1-INH massively 
reduced the lesion size and significantly improved neurological and functional 
outcome in young male mice when C1-INH was applied 1 hour after onset of tMCAO. 
Of great importance is the finding that high dose of 15.0 U C1-INH was still effective 
in a delayed setting, i.e. 6 hours after ischemia. C1-INH positively influenced 
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neurological behavior, although beneficial effects on infarct size could no longer be 
observed under these conditions. This finding demonstrates that it is possible to 
improve outcome without affecting infarct size. This discrepancy is probably 
attributable to the relatively poor correlation between infarct volumes and 
neurological deficits. Conflicting results have already been demonstrated in animal 
models of ischemic stroke (Wahl et al., 1992; Kawamata et al., 1996; Kleinschnitz et 
al., 2007; Kraft et al., 2010b) but also in human stroke patients (Pineiro et al., 2000). 
Thus, high dose of 15.0 U C1-INH even at a delayed setting of application is 
promising for the development of new pharmaceuticals for human stroke therapy. 
Furthermore, long-term evaluation of ischemic mice early injected with 15.0 U C1-
INH on the basis of MRI (day 1, 7) and functional scoring impressively demonstrated 
sustained neuroprotection from focal cerebral ischemia. This finding confirmed 
previous observations that revealed a similar effect of C1-INH application (De Simoni 
et al., 2004). 
If the MCA occlusion is permanent as it is the case in the model of pMCAO, the 
severe perfusion disturbance persists, and infarcts are not reperfused. The present 
observation that protective effects seen in tMCAO were lost after permanent 
occlusion of the MCA strikingly indicates that C1-INH targets processes at the 
neurovascular interface involved in I/R injury. However, permanent ischemia similarly 
to transient ischemia ultimately leads to brain edema formation. Another explanation 
for the ineffectiveness of C1-INH in pMCAO might be that C1-INH does not gain 
sufficient access to the infarct region due to intravascular thrombosis as suggested 
by De Simoni et al. (2003).  
Although, 15.0 U C1-INH has been demonstrated to be effective in the murine model 
of tMCAO, C1-INH doses used here cannot be directly compared with the human 
situation. This is indicated by the observation that the plasma half-life time of 
clearance (t1/2) of C1-INH in mice and rats is ~9 hours (Dickneite, 1993), whereas in 
healthy humans the C1-INH plasma t1/2 has been reported to range between 28 
hours (Caliezi et al., 2000) and 35 hours (de Zwaan et al., 2002). In contrast to the 
present findings, another plasma derived C1-INH used by De Simoni et al. (2004) 
showed a rather narrow therapeutic time window after focal cerebral ischemia, i.e. 30 
min, but was ineffective already after 60 min. To date, the exact reasons for this 
mismatch are ambiguous but differences in the duration of brain ischemia (30 min vs. 
60 min) or the used C1-INH preparations might play a role. The latter is further 
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underlined by the fact that in the present study 7.5 U C1-INH had only small effects 
on stroke outcome, whereas the minimal effective dose in mice used by De Simoni et 
al. (2004) was 5.0 U.  
Despite discrepancies concerning the doses of C1-INH in different reports, our data 
obtained from blood-sensitive MRI studies, at least, demonstrate that exogenously 
applied high dose of 15.0 U C1-INH was not correlated with increased risk of 
intracerebral bleeding in mice at any time point of data acquisition (day 1, 7). This 
finding is of critical relevance since C1-INH interferes with the coagulation system via 
inhibition of FXIIa. This observation corresponds to our previous experience after 
FXIIa blockade (Kleinschnitz et al., 2006; Hagedorn et al., 2010). In line with this, no 
effect on hemostasis as assessed by tail bleeding assays was observed after 
treatment with 15.0 U C1-INH. Hence, normal hemostasis was not affected by 
excessively applied C1-INH.  
Moreover, the present study found that high dose of 15.0 U C1-INH did not interfere 
with cardiovascular function as assessed by heart rate and mean arterial blood 
pressure. 
Noteworthy, from a translational perspective, the C1-INH used in this study is already 
approved since 2009 for replacement therapy of C1-INH during acute attacks of 
hereditary angioedema (HAE) (Craig et al., 2009). To date, there are no major safety 
concerns (Banerji, 2010; Keating, 2009), although it is obvious that compensation of 
naturally lacking C1-INH in patients with HAE and rising of C1-INH levels above the 
normal range in stroke patients reflect different conditions. 
As brain ischemia is usually a disease of the elderly (Di Carlo et al., 1999) a potential 
neuroprotective compound is recommended to be tested not only in young laboratory 
animals but also in older cohorts (Fisher et al., 2009; Macleod et al., 2009). Other 
members of our research group, therefore, focused on older animals. The 
corresponding data were included in a common publication (Heydenreich et al., 
2012). Interestingly, the beneficial activity of 15.0 U C1-INH was preserved in male 
middle-aged mice (6 month) and old mice (12 month) similarly subjected to 1 hour of 
tMCAO. These animals displayed significantly smaller infarct sizes and ameliorated 
neurological behaviour following treatment with 15.0 U C1-INH 1 hour post stroke 
compared with corresponding Ctrl mice. Hence, these findings validated our present 
results obtained from young laboratory mice.  
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Not only age can result in differences in stroke development, but also gender 
influences outcome after brain ischemia (Fisher et al., 2009; Macleod et al., 2009). 
Importantly, beneficial effects of 15.0 U C1-INH on infarct volumes and neurological 
performance could also be demonstrated in young female mice injected with C1-INH 
1 hour after onset of ischemic stroke (data included in Heydenreich et al., 2012). 
To confirm our data and to exclude a species-specific effect, collaborating 
researchers from CSL Behring (Marburg, Germany) investigated the effect of C1-INH 
on stroke development in young male CD rats (data included in Heydenreich et al., 
2012). Animals subjected to 1.5 hours tMCAO and injected with 20 U/kg C1-INH 1.5 
hours after onset of ischemia displayed reduced infarct sizes and performed 
significantly better in neurological and motility tests compared with vehicle-treated 
control rats on day 1 following stroke, confirming our present findings obtained with 
mice. 
In summary, our results revealed that application of 15.0 U C1-INH early after onset 
of ischemia largely reduced lesion size and neurological deficits, when concomitantly 
reperfusion was restored. Delayed treatment, at least, improved neurological and 
motor function of mice, but not infarct size. Moreover, the neuroprotective effect was 
long-lasting and sustained over an observational period of 7 days in the present 
study. Importantly, C1-INH did not affect normal hemostasis, accordingly did not 
induce intracerebral bleeding complications after focal cerebral ischemia and did not 
interfere with cardiovascular function or other physiological parameters. 
 
4.2 The protective role of C1-inhibitor relies on its combined antiedematous, 
antiinflammatory and antithrombotic mechanisms 
C1-INH represents an interesting compound with a wide spectrum of inhibitory 
activities that do not exclusively depend on its protease inhibiting function. C1-INH 
controls the plasma kallikrein-kinin system (KKS) at multiple levels by regulating 
activation of coagulation factor FXII and plasma kallikrein and the intrinsic 
coagulation pathway by blocking activity of FXIa. Additionally, C1-INH is the main 
inhibitor of all three pathways of the innate complement system. On the other hand, 
ischemic stroke triggers processes that contribute to secondary deterioration such as 
edema formation and inflammation. The importance of the plasma KKS in stroke 
development was recently highlighted by studies performed in our group. Following 
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inhibition of components of the murine plasma KKS, the bradykinin receptor 1 (B1R) 
(Austinat et al., 2009) and the serine protease kininogen (Langhauser et al., 2012), 
both acting downstream of FXIIa, genetically modified mice were protected from 
ischemic stroke. This was due to reduced edema formation and a less pronounced 
inflammatory response.  
Remarkable, in the present study treatment with 15.0 U C1-INH 1 hour post stroke 
resulted in stabilization of the blood-brain-barrier (BBB) which was indicated by highly 
reduced Evans blue extravasation into ischemic brain parenchyma and consequently 
less edema formation as assessed by the wet/dry weight method within ischemic 
mouse brains following tMCAO. This effect was also seen in areas regularly 
undergoing infarction, the basal ganglia, in both sham-operated and C1-INH-treated 
mice following tMCAO (Stoll et al., 2008). Despite a visible ischemic lesion upon TTC 
staining, the basal ganglia showed no Evans blue extravasation upon 15.0 U C1-INH 
treatment indicating preservation of the BBB within the infarcts. This finding is of 
special importance, since small infarcts are always present in basal ganglia despite 
successful antithrombotic treatments as it was demonstrated by 1 hour tMCAO 
studies. In contrast, delayed treatment 6 hours after stroke onset could not 
counteract BBB destabilization. This was indicated by almost identical levels of 
Evans blue extravasation into the brain parenchyma and edema formation between 
vehicle and C1-INH-treated groups. Similar negative results were obtained in the 
model of pMCAO, indicating that C1-INH protects BBB integrity only when 
reperfusion is achieved within less than 6 hours after stroke induction.  
In this study the tight junction protein occludin could be shown to be preserved by 
C1-INH application 1 hour after tMCAO as assessed by Western blot analysis and 
immunohistochemistry. According to our findings, loss of occludin has recently been 
reported to contribute to BBB disruption in models of tMCAO (Yang et al., 2007; Liu 
et al., 2012). Moreover, the BBB stabilizing effects in mice mediated by C1-INH could 
also be confirmed in another species, i.e. rats showing less edema formation when 
20 U/kg C1-INH was applied 1.5 hours after onset of ischemic stroke (data included 
in Heydenreich et al., 2012). Additionally, rats showed almost no BBB disturbance in 
ischemic basal ganglia, although infarcts have been regularly present in this region, 
like in C1-INH-treated mice. This further indicates that the lesser edema formation 
seen in the C1-INH-treated mice of the present study was a specific phenomenon 
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secondary to minor damaging effects at the BBB and not simply due to smaller infarct 
volumes in these animals. 
In line with BBB stabilization as seen upon early C1-INH application after onset of 
tMCAO, almost no induction of Edn-1, a key regulator of BBB functions, could be 
observed in 15.0 U C1-INH-treated mice. Pharmacological blockade of Edn-1 has 
already been demonstrated to result in attenuated ischemic brain injury, edema 
formation and BBB disruption in rats (Dawson et al., 1999; Matsuo et al., 2001).  
As stroke development is accompanied by a robust inflammatory response, the 
finding of the present study that infiltration of leukocytes (macrophages/neutrophils) 
into ischemic brain parenchyma was limited following application of 15.0 U C1-INH is 
of interest. In this context, it has previously been shown that C1-INH holds the 
potential to bind to adhesion molecules (E- and P-selectins) expressed on cell 
surfaces of e.g. endothelial cells (Cai & Davis III, 2003; Cai et al., 2005). Since 
selectins are highly important for the regulation of cell migration, those interactions 
might interfere with cell recruitment to sites of inflammation (De Simoni et al., 2004; 
Cai et al., 2005; Storini et al., 2005; Gesuete et al., 2009), but also serve to adhere 
C1-INH on injured brain endothelial walls, thereby controlling local activation of 
contact-kinin system proteases (Cai & Davis III, 2003). The latter is emphasized by 
the very recent finding of Marion Hofmeister from the group of Dr Marc Nolte (CSL 
Behring GmbH, Marburg, Germany), who impressively demonstrated that exogenous 
applied C1-INH was highly concentrated in the microvasculature of ischemic but not 
contralateral (healthy) hemispheres following tMCAO. These data have been 
published in a shared paper (Heydenreich et al., 2012). In line with our findings, 
Storini et al. (2005) reported on the reduction of CD11b+ (specific surface marker for 
macrophages/microglia) cells after C1-INH treatment, and Gesuete et al. (2009) 
found a reduced number of infiltrated leukocyte-like cells. 
Cerebral ischemia also induces release of cytokines, e.g. the proinflammatory 
cytokines IL-1β and TNF-α, which have been detected 2-6 hours post stroke (Wang 
et al., 1994). In our study, the induction levels of the proinflammatory cytokines IL-1β 
and TNF-α in vehicle-treated mice 24 hours after onset of ischemia were extremely 
elevated, compared with a significantly lower induction in mice treated with 15.0 U 
C1-INH. This finding is important since actions of these cytokines after brain injury 
have been proposed to be toxic and to increase tissue damage (Rothwell & Relton, 
1993; Scherbel et al., 1999). Similar, the antiinflammatory cytokines IL-10 and  
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TGFβ-1 after application of 15.0 U C1-INH were less induced 24 hours post stroke. 
These findings are in accordance with previous data relying on late phase (48 hours) 
observations (Storini et al., 2005). However, in the same study the induction of IL-10 
in the early phase (4 hours) after stroke was significantly elevated after C1-INH 
treatment compared with sham-operated and saline-treated animals. At later stages 
IL-10 induction in C1-INH-treated mice dropped and was found to be significantly 
lower compared with controls 48 hours after stroke. Storinis data point to a C1-INH-
mediated shift from the pro- to the antiinflammatory status in the early phase of 
stroke, which, underlined by our results, is compensated at 24 hours or later phases 
of ischemia (48 hours). In our study cytokine levels 1 day after stroke were 
significantly reduced in general by C1-INH action, which argues for a secondary 
effect due to smaller infarcts, rather than a direct impact mediated by C1-INH at this 
time.  
Additional to the plasma KKS, the intrinsic pathway of blood coagulation with FXIIa 
representing an interface between both pathways, displays another critical issue in 
preventing stroke development. For decades, it was assumed that FXII is not 
relevant for blood clotting and dispensable for normal hemostasis (Mackman, 2004) 
since human FXII deficiency is not associated with an abnormal bleeding phenotype 
(Renné et al., 2005). However, this hypothesis was very recently challenged by our 
group and collaborators demonstrating that FXII deficiency in mice due to genetic 
disruption (Kleinschnitz et al., 2006) or pharmacological inhibition (Hagedorn et al., 
2010) protected from ischemic neurodegeneration by preventing microvascular 
thrombosis without increasing the risk of intracerebral bleeding.  
Remarkably, application of 15.0 U C1-INH 1 hour following tMCAO resulted in 
massively decreased generation of intracerebral fibrin and higher patency of 
microvessels within the ischemic brain parenchyma in mice. However, this effect on 
fibrin(ogen) accumulation was no longer observed when C1-INH was injected in a 
delayed setting (6 hours) in the reperfusion-dependent model. Because thrombosis 
or edema formation under delayed treatment conditions were not affected by C1-INH 
treatment, additional mechanisms apart from those reported here and not yet clarified 
are responsible for the improved neurological behavior in ischemic mice. Given the 
profound antithrombotic effect of C1-INH 1 hour after tMCAO, the present 
observation that C1-INH failed to protect from stroke after pMCAO is coherent 
because clot formation is unlikely to be influenced in the absence of tissue 
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reperfusion, i.e. under conditions of persistent occlusion of a large proximal brain 
vessel like the MCA. Accordingly, C1-INH treatment had no effect on fibrin(ogen) 
formation after pMCAO. Moreover, the actual finding in the pMCAO model mirrors 
previous observations of our group in FXII deficient mice (Pham et al., 2010) as well 
as kininogen deficient mice (Langhauser et al., 2012) and indicates that blocking of 
the contact-kinin system after stroke is only promising if tissue reperfusion can be 
achieved in parallel. The present findings obtained by Western blot analysis and 
immunohistochemistry demonstrate that 15.0 U C1-INH application early after stroke 
induction interferes with microvascular thrombosis, but only when reperfusion is 
restored. 
Besides its impressive regulatory action on components of the contact-kinin system, 
C1-INH is also the major inhibitor of all three pathways of the innate complement 
system, which is activated upon human stroke (Pedersen et al., 2004) as well as in 
experimental models of cerebral ischemia (Pasinetti et al., 1992; Huang et al., 1999; 
Schäfer et al., 2000; Van Beek et al., 2000). This study cannot appreciate to what 
extent suppression of the innate complement system contributed to the profound 
antiischemic effects of C1-INH (Davis III et al., 2008). De Simoni et al. (2004) found 
that mice deficient for C1q of the classical pathway of the complement system, which 
displayed a trend towards smaller infarct size following tMCAO, developed 
significantly smaller infarctions after C1-INH treatment. This finding indicates that C1-
INH actions in brain protection are, at least, independent from activation of the 
classical pathway of the innate complement system.  
Summarized, our data demonstrate that treatment with 15.0 U C1-INH post stroke 
affects different cellular pathways that critically contribute to brain damage involving 
the plasma KKS and the intrinsic pathway of blood coagulation. C1-INH applied at 1 
hour after tMCAO resulted in (1) stabilization of the BBB and reduced brain edema, 
(2) less inflammation and secretion of inflammatory cytokines and (3) decreased 
microvascular thrombosis. Hence, C1-INH represents a promising compound for 
treatment of I/R injury, but not permanent cerebral ischemia.  
Whereas the antiinflammatory properties of C1-INH are well established in models of 
I/R injury of different organ systems (Horstick et al., 1997; Lehmann et al., 2000; 
Nielsen et al., 2002), including the central nervous system (CNS) (De Simoni et al., 
2003; Storini et al., 2005; Gesuete et al,. 2009; Longhi et al., 2009) the present 
description of C1-INH as powerful antithrombotic and antiedematous compound is 
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new and further adds to our understanding of this multifaceted molecule. 
Furthermore, our data underline the existence of an important crosstalk between 
microvascular thrombosis and inflammation within the scope of brain ischemia. Thus, 
cerebral ischemia was recently proposed to be a “thromboinflammatory” disorder 
(Nieswandt et al., 2011; Stoll et al., 2010). 
Given the pleotropic actions of C1-INH the contribution of each of these processes 
(BBB stabilization, inflammation and thrombosis) to the development of ischemic 
brain lesions is difficult to dissect and would require continuous in vivo imaging of 
cell-cell interactions at the neurovascular unit. However, the fact that C1-INH is able 
to block different pathways could be of great advantage since therapeutical 
approaches targeting single pathways so far failed during translation from laboratory 
animals to stroke patients (O'Collins et al., 2006).
 
 
4.3 Functional outcome after ischemic stroke is improved in the absence of 
macrophage-restricted adhesion molecule sialoadhesin  
As ischemic stroke is accompanied by a pronounced inflammatory response (Stoll et 
al., 1998; Wang et al., 2007), signaling molecules which guide immune cell functions 
are of special interest for investigations of new therapeutical options to counteract 
stroke development. Most of those signaling molecules are widely expressed on 
many types of immune cells. In contrast, expression of Sn, a cell adhesion molecule 
of yet unknown function, is restricted to macrophage-like cells and upregulated 
during inflammation. Therefore, Sn might represent a suitable target to analyze 
macrophage-specific function in focal cerebral ischemia.  
The present results revealed that Sn expression is absent on cells within healthy 
brain parenchyma, confirming previous findings (Perry et al., 1992). However, Sn 
was found to be expressed on cells located around brain vessels. Ascribed to their 
position, these Sn+ cells might be perivascular macrophages (Guillemin & Brew, 
2004). These cells represent a very heterogeneous population of bone marrow-
derived phagocytes that are found adjacent to brain vessels. Perivascular 
macrophages have been demonstrated to be activated in different models of CNS 
inflammation, including stroke, and they are supposed to function as 
immunmodulatory cells (Williams et al., 2001). In line with the present finding, 
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Hartnell et al. (2001) reported on perivascular macrophages expressing Sn under 
steady-state (healthy) conditions. 
Importantly, the present results confirm findings by Perry et al. (1992) that Sn 
expression can be detected on cells within brain parenchyma after reperfusion-
induced breakdown of the BBB. Permeability studies of the present thesis following 
tMCAO in WT (Sn+/+) mice using the vascular tracer Evans blue support the previous 
hypothesis that expression of Sn can be regulated by different stimuli including 
serum factors, which might enter the brain parenchyma due to BBB disruption (Perry 
et al., 1992). However, there is no definite proof, whether Sn is expressed on 
activated microglia or recruited macrophages or both. The migration of Sn+ 
perivascular macrophages from brain vessels to sites of brain injury might also be 
conceivable. Challenging, microglia become activated following cerebral ischemia 
and change their typical ramified morphology to a roundish shape. Thus, they 
become indistinguishable from infiltrating hematogenous macrophages on 
morphological grounds (Stoll et al., 1998). Additionally, microglia and macrophages 
share most cell surface markers such as CD11b (Flaris et al., 1993), which further 
exacerbate their distinction. Since detailed analyses on the origin of macrophage-like 
cells were not included in this study, the pool of macrophages within the ischemic 
parenchyma always contained activated microglia to an uncertain amount. 
The present thesis revealed that mice, homozygous deficient for Sn displayed 
infarcts of similar size as WT mice. However, absence of Sn was associated with 
significantly improved neurological and motor function and coordination. A 
discrepancy between infarct size and functional outcome is not unusual in 
experimental stroke studies (Wahl et al., 1992; Kawamata et al., 1996; Kleinschnitz 
et al., 2007; Kraft et al., 2010b) and was reported already for the delayed treatment 
with C1-INH (4.1). Importantly, follow-up MRI revealed no secondary infarct growth 
between day 1 and 3 in Sn-/- mice, demonstrating sustained protection from 
secondary deterioration. Functional tests additionally performed at more advanced 
stage of stroke development (day 3) showed less severe neurological and motor 
deficits in Sn-/- mice compared with WT animals. Similar in the clinical setting, 
improvement of functional outcome is more important than mere reduction of infarct 
size. 
Interestingly, Gliem et al. (2012) impressively demonstrated that depletion of 
monocytes/macrophages caused bleeding complications at advanced stages of 
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cerebral ischemia (day 3) in mice. Importantly, in our study blood-sensitive MRI 
performed in Sn-/- mice at day 1 and 3 after tMCAO demonstrated that absence of Sn 
on macrophages was not associated with an increased risk of intracerebral 
hemorrhage, indicating that Sn expression itself is not involved in critical steps to 
maintain the integrity of the BBB following ischemic brain injury. 
Summarized, the results presented here revealed that Sn deficiency on 
macrophages was associated with improved neurological and motor function 24 
hours after stroke onset, but did not influence lesion volumes. Moreover, the 
neuroprotective effect persists, at least, till day 3 of cerebral ischemia. Importantly, 
absence of Sn was neither accompanied with intracerebral bleeding nor secondary 
infarct growth even at a more advanced stage of ischemia. 
 
4.4 Sialoadhesin deficiency correlates with reduced inflammatory response 
and less blood-brain-barrier disruption 
Importantly, the present study revealed that the integrity of the BBB 24 hours after 
tMCAO was less disturbed in absence of Sn compared with WT littermates. One 
possible explanation might be that Sn is involved in activation of other immune cells 
via cell-cell interactions, as it was already proposed by other investigators (Crocker et 
al,. 1990, 1995; van den Berg et al., 1992, 2001; Müerköster et al., 1999; Munday et 
al., 1999; Hartnell et al., 2001). Without or with less cell-cell interactions due to Sn 
deletion, less immune cells would be activated followed by a reduced release of 
immune mediators like metalloproteinases, which have been demonstrated to be 
involved in damage of the BBB by degradation of BBB proteins (Yang et al., 2007; 
Liu et al., 2012). In line with this, the number of activated CD11+ 
macrophages/microglia found in ischemic lesions in Sn-/- mice on day 1 after tMCAO 
was significantly reduced. These findings point to a role of Sn in activation or 
recruitment of, at least, CD11b+ immune cells following stroke, and might culminate 
in reduced damage of the BBB and less neurological and motor deficits. Accordingly, 
data obtained from other investigators demonstrated improved outcome in a model of 
hereditary neuropathies due to less macrophage and T cell recruitment in Sn null 
mice (Kobsar et al., 2006; Ip et al., 2007). 
Surprisingly, semiquantitative RT-PCR analysis of relative expression levels of 
proinflammatory cytokines IL-1β and TNF-α 24 hours after ischemia revealed no 
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differences between Sn-/- mice and WT littermates, although the number of CD11b+ 
cells in Sn-/- mice was reduced. This finding indicates that absence of Sn on 
macrophages does not obviously affect induction of these cytokines at 24 hours and 
suggest other cells than macrophages (Rothwell & Relton, 1993) as main source of 
cytokine release, e.g. glia cells or endothelial cells (Barone & Feuerstein, 1999; del 
Zoppo et al., 2000). So far, we cannot definitely say that Sn deficiency does not 
affect cytokine expression at later time points, when macrophage/microglia infiltration 
reaches peak levels (Gliem et al., 2012). However, from this point of view, it seems 
likely that macrophage-like cells are not harmful by release of proinflammatory 
cytokines (e.g. IL-1β, TNF-α) 24 hours after onset of ischemia, at least, in the model 
of tMCAO. 
In summary, the present findings provide evidence that deletion of Sn counteracts 
BBB disruption and demonstrate that Sn deficiency was associated with reduced 
activation and infiltration of CD11b+ macrophages/microglia into ischemic brains. This 
might be a result of modified interactions between Sn deficient macrophage-like cells 
and other immune cells and in consequence, might account for less neurological 
deficits observed in Sn-/- mice. Although the expression of macrophages/microglia-
specific surface marker CD11b was reduced, no alterations in the expression levels 
of proinflammatory cytokines 24 hours upon cerebral ischemia could be detected. 
This indicates that functional effects of Sn deficiency cannot be attributed to reduced 
cytokine levels. 
 
4.5 Macrophage-specific nuclear factor-kappa B activation does not contribute 
to stroke development 
In a further approach to shed light on the macrophage-specific contribution to stroke 
development, LysM-Cre+/-/IKK2fl/fl mice lacking NF-ϰB function in macrophages, were 
included in our study. Since full IKK2 knockout mice die from TNF-dependent liver 
apoptosis in the embryonic phase (Tanaka et al., 1999), a conditional mouse model 
with deletion of IKK2 restricted to the myeloid cell lineage, including macrophages, 
was used (Kanters et al., 2003). Due to this deletion, NF-ϰB cannot be activated in 
macrophages of LysM-Cre+/-/IKK2fl/fl mice. Consequently, genes regulated by NF-ϰB 
will not be activated, e.g. genes that code for proinflammatory cytokines (Pahl, 1999). 
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Interestingly, in the present thesis lack of NF-ϰB activity in macrophages did not 
affect lesion size or neurological outcome in mice 24 hours after onset of ischemia. 
Findings from other groups regarding the role of NF-ϰB are highly controversial. 
Some provide data demonstrating protection from experimental stroke by inhibition of 
NF-ϰB activation via a pharmacological approach (Khan et al., 2005) or in a model of 
constitutive p50 (subunit of NF-ϰB) knockout (Schneider et al., 1999). In contrast, 
others report on a detrimental effect of NF-ϰB inhibition via p50 deficiency in different 
models of MCAO (Duckworth et al., 2006; Li et al., 2008). However, findings from 
conventional knockout models like p50 deficiency cannot easily be compared with 
results obtained from a tissue-specific conditional knockout (i.e. IKK2 deletion) 
model, since the latter provides cell-specific data contrary to complete deletion of the 
target gene in all cell types in a full knockout model.  
Summarized, mice with a NF-ϰB activation defect in macrophages did not show 
neurological improvements or reduced tissue damage after tMCAO, though 
macrophages are not able to secrete proinflammatory cytokines, e.g. IL-1β or TNF-α 
underlying the control of NF-ϰB. 
 
4.6 Concluding remarks and future perspective 
This thesis constitutes C1-INH Berinert® P as an attractive and promising 
pharmacological target in acute cerebral ischemia, since (1) C1-INH treatment 
protects from stroke in different clinical scenarios, (2) C1-INHs modes of action are 
multimodal, and (3) C1-INH is already used as pharmacological treatment in humans. 
Hence, these findings should be taken as a basis for further translational studies in 
relevant large animal models, which are a crucial requirement to develop safe 
preclinical protocols in biomedical research. 
The second part of this thesis provides novel data about the role of macrophages in 
the acute phase of stroke using two different approaches of genetically modified 
mouse models. Our results provide evidence that macrophages are not the main 
source of proinflammatory cytokines and that macrophage-specific synthesis of 
proinflammatory cytokines under the regulation of NF-ϰB does not contribute to 
neurological deficits and brain damage early after cerebral ischemia. Hence, this 
thesis suggest a role for macrophages as bystanders of ischemic deterioration, as 
rather critical effector cells, at least, in the early phase of cerebral ischemia.  
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6 APPENDIX 
Abbreviations 
Ab   antibody 
ANOVA  analysis of variance 
APS   ammonium peroxide disulfate 
ATPase  adenosintriphosphatase 
AU   arbitrary units 
BBB   blood-brain-barrier 
BCA   bicinchoninic acid 
BK   bradykinin 
B1R/B2R  bradykinin receptor 1/2 
bp   base pairs 
BSA   bovine serum albumin 
Ca2+   calcium 
CBF   cerebral blood flow 
CCA   common carotid artery 
cDNA   copy DNA 
CD11b  cluster of differentiation 11b 
C1-INH  C1-inhibitor 
CISS    constructed interference in steady state 
Cl-    chloride 
CNS   central nervous system 
CP   carboxypeptidases 
CT   computed tomography 
Ctrl   control 
Cy3   indocarbocyanin 
DAB   3,3`- diaminobenzidin 
ddH2O  double distilled water 
DEPC   diethyldicarbonat 
des-Arg9-BK  des-arginine9-bradykinin 
DNA   deoxyribonucleic acid 
dATP   deoxyadenosine triphosphate 
dCTP   deoxycytidine triphosphate 
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dGTP   deoxyguanosine triphosphate 
dTTP   deoxythymidine triphosphate 
dNTP   deoxyribonucleotide triphosphates 
ECA   external carotid artery 
ECL   enhanced chemiluminescence 
ECM   endothelial cell membrane 
Edn-1   endothelin-1 
EDTA   ethylenediaminetetraacetic acid 
EtBr   ethidium bromide 
EtOH   ethanol 
FDA   Food and Drug Administration 
FIX, FX, FXI, FXII coagulation factor IX, X, XI, XII 
(FIX/FX/FXI/FXII)a activated form of FIX/FX/FXI/FXII 
fl   floxed 
GAPDH  glyceraldehyde 3-phosphate dehydrogenase 
GPCR  G-protein coupled receptor 
HAE   hereditary angioedema 
H&E   hematoxylin/eosin 
HMWK  high molecular weight kininogen 
H2O2   hydrogen peroxide 
HRP   horseradish peroxidase 
ICA   internal carotid artery 
ICAM-1  intercellular adhesion molecule-1 
Ig   immunoglobulin 
IgG   immunoglobulin G 
IgM   immunoglobulin M 
IL-1β   interleukin-1beta 
IϰB   inhibitor of NF-ϰB 
IKK2   IϰB kinase 2 
i.p.   intraperitoneal 
I/R   ischemia/reperfusion 
i.v.   intravenous 
K+   potassium 
KCl   potassium chloride 
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kDa   kilo Dalton 
kg   kilogram 
KKS   kallikrein-kinin system 
mAB   monoclonal antibody 
MCA   middle cerebral artery  
MCAO  MCA occlusion 
MeOH  methanol 
MgCl2   magnesium chloride  
min   minute(s) 
mM   milli molar 
MRI   magnetic resonance imaging 
mRNA  messenger ribonucleic acid 
Na+   sodium 
NaCl   sodium chloride 
Na2HPO4   disodium hydrogen phosphate 
NaH2PO4  sodium dihydrogen phosphate 
NaOH   sodium hydroxide 
NF-ϰB  nuclear factor-kappa B 
NO   nitric oxid 
NP-40   NonidetTMP40 
pAB   polyclonal antibody 
PAGE   polyacrylamide gel electrophoresis 
PBS   phosphate buffered saline 
PBST   PBS Tween 
PCR   polymerase chain reaction 
PFA   paraformaldehyde 
PK   prekallikrein 
pMCAO  permanent MCAO 
POD   peroxidase 
polyP   polyphosphate(s) 
PVDF   polyvinylidene fluoride 
RT-PCR  real time PCR 
rCBF   regional CBF 
RIPA   radio-immunoprecipitation assay 
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RNase  ribonuclease 
ROS   reactive oxygen species 
rpm   revolution per minute 
rt-PA   recombinant tissue plasminogen activator 
sec   second(s) 
SER   sheep erythrocyte binding receptor 
Serpin  serine protease inhibitor 
SD   standard deviation 
SDS   sodium dodecyl sulfate 
Siglec   sialic acid immunoglobulin-like lectins 
Sn   sialoadhesin 
Sn-/-   sialoadhesin deficient 
Sn+/+   sialoadhesin expressing 
T1/2   half-life time of clearance 
T2*w   T2*weighted 
TAE   TRIS base-acetic acid-EDTA 
Taq   thermophilus acquaticus 
TBS   TRIS buffered saline 
TBST   TBS Tween 
TEMED  tetramethylethylenediamine 
TG   transgenic 
TGFβ- 1  transforming growth factor beta-1 
tMCAO  transient MCAO 
TNF-α  tumor necrosis factor-alpha 
TRIS   tris(hydroxymethyl)-aminomethan 
TTC   2,3,5-triphenyltetrazolium chloride 
Tween  polyoxyethylenesorbitan monolaurate 
U   units 
WT   wildtype 
vs.   versus 
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